{
  "directed": true,
  "graph": {
    "annotation_list": {},
    "annotation_pattern": {
      "Species": "^\\d+$"
    },
    "annotation_url": {
      "Anatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno",
      "Cell": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno",
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno",
      "Disease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno",
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno",
      "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno"
    },
    "document_metadata": {
      "authors": "Sandra Spalek",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "copyright": "Copyright © 2018 Fraunhofer Institute SCAI, All rights reserved.",
      "description": "",
      "licenses": "CC BY 4.0",
      "name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies",
      "version": "1.0.0"
    },
    "namespace_pattern": {
      "PUBCHEM": "^\\d+$"
    },
    "namespace_url": {
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns",
      "CONSO": "https://raw.githubusercontent.com/pharmacome/conso/501ceccdc9a27d97edbdc48a89ebe8e1dd3626e9/export/conso-names.belns",
      "FPLX": "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/terminology/a5b84013a08880975ca84f40999e4404b14a97e2/external/go-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns",
      "INTERPRO": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/interpro-names.belns",
      "MESH": "https://raw.githubusercontent.com/pharmacome/terminology/01c9daa61012b37dd0a1bc962521ba51a15b38f1/external/mesh-names.belns"
    },
    "path": "tau/miyata2011.bel",
    "pybel_version": "0.14.10"
  },
  "links": [
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Tauopathies are a family of neurodegenerative disorders characterized by the appearance of aggregates of the microtubule-associating protein, tau.",
      "key": "69274d7d7b168641202cd1ee8eaec2ab",
      "line": 84,
      "relation": "increases",
      "source": 22,
      "target": 117
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "For example, tau pathology closely correlates to neuron loss and cognitive deficits",
      "key": "ae96e52d8ecaed3fd00dbc1c8be924f3",
      "line": 90,
      "relation": "positiveCorrelation",
      "source": 117,
      "target": 43
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "For example, tau pathology closely correlates to neuron loss and cognitive deficits",
      "key": "a1edfa55228bd84a4f6e9adcd531d94e",
      "line": 91,
      "relation": "negativeCorrelation",
      "source": 117,
      "target": 51
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "For example, tau pathology closely correlates to neuron loss and cognitive deficits",
      "key": "23877a1a6195647bfaff53918f6a2b28",
      "line": 90,
      "relation": "positiveCorrelation",
      "source": 43,
      "target": 117
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "For example, tau pathology closely correlates to neuron loss and cognitive deficits",
      "key": "443be49aa90c0340b7d593933e1f3737",
      "line": 91,
      "relation": "negativeCorrelation",
      "source": 51,
      "target": 117
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "There are no cures for any tauopathy. Neuroprotective agents, such as acetylcholinesterase inhibitors and NMDA antagonists, have been approved for use in the clinic, based on their ability to slow the rate of cognitive decline in patients with moderate to severe AD (reviewed in [36])",
      "key": "8a175bcbc2757ac9e28e19a58db6e175",
      "line": 139,
      "relation": "positiveCorrelation",
      "source": 51,
      "target": 33
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "There are no cures for any tauopathy. Neuroprotective agents, such as acetylcholinesterase inhibitors and NMDA antagonists, have been approved for use in the clinic, based on their ability to slow the rate of cognitive decline in patients with moderate to severe AD (reviewed in [36])",
      "key": "bdb5abbc68dcc7d9b971ec3c2bb1fca2",
      "line": 140,
      "relation": "positiveCorrelation",
      "source": 51,
      "target": 1
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Phosphorylation of tau by the kinases GSK3b, Cdk5 and MARK2 is a major regulator of its microtubule interactions",
      "key": "b74b6fff8e4caa3fb2b67228bac44c7b",
      "line": 97,
      "relation": "directlyIncreases",
      "source": 90,
      "subject": {
        "modifier": "Activity"
      },
      "target": 97
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Importantly, MARK2-based phosphorylation of tau is accelerated by the priming activity of either Cdk5 or GSK3b [29], suggesting that tau phosphorylation involves a series of ordered kinase events.",
      "key": "012f383cc249417b4e974662d13aba83",
      "line": 108,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 90,
      "target": 101
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Phosphorylation of tau by the kinases GSK3b, Cdk5 and MARK2 is a major regulator of its microtubule interactions",
      "key": "aff208b225723fed8705cdf40f2e4419",
      "line": 100,
      "relation": "regulates",
      "source": 97,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "In general, phosphorylation of tau reduces its affinity for microtubules [30], while dephosphorylation via enzymes such as PP2A and PP5 restores binding",
      "key": "be725fc4d272f7c358d18a1fe4dd7854",
      "line": 116,
      "relation": "decreases",
      "source": 97,
      "target": 56
    },
    {
      "key": "363653ff1cab53cb1b62df177949d94f",
      "relation": "partOf",
      "source": 97,
      "target": 76
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "However, another related BAG family member, BAG2, interacts with Hsp70 and tau but, unlike BAG1, assists clearance of phosphorylated tau [132]",
      "key": "89ffaa5300431da5becd7c78a2d6454b",
      "line": 486,
      "relation": "association",
      "source": 97,
      "subject": {
        "modifier": "Degradation"
      },
      "target": 86
    },
    {
      "key": "064f60bbd4e86ec0d71e89e733af2e71",
      "relation": "hasVariant",
      "source": 95,
      "target": 97
    },
    {
      "key": "8b6b9bc97989061618adf5b808da8142",
      "relation": "partOf",
      "source": 95,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "In general, phosphorylation of tau reduces its affinity for microtubules [30], while dephosphorylation via enzymes such as PP2A and PP5 restores binding",
      "key": "05cdde93b0f6ee26479f82cece74b0cb",
      "line": 117,
      "relation": "increases",
      "source": 95,
      "target": 56
    },
    {
      "key": "b5ef526ab5a17da51fd96bb875e02aac",
      "relation": "hasVariant",
      "source": 95,
      "target": 96
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Brain": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Interestingly, tau clearance is known to be impaired in the aging brain [45], supporting the idea that diminished quality control might be conducive to certain tauopathies, such as AD, which are linked to aging",
      "key": "336f435329b117ae94128b7023adef88",
      "line": 177,
      "relation": "negativeCorrelation",
      "source": 95,
      "subject": {
        "modifier": "Degradation"
      },
      "target": 49
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Furthermore, recent evidence suggests that tau is essential for the neurotoxicity of amyloid-b, providing a possible link between these classic AD targets and suggesting that reductions in tau levels might be important via multiple, beneficial mechanisms [46–48]",
      "key": "15f0c3fb1eb56be13f5ce737e8f0b569",
      "line": 187,
      "relation": "increases",
      "source": 95,
      "target": 114
    },
    {
      "key": "ed64f6f261cfc8877aa67011f6730b15",
      "relation": "hasVariant",
      "source": 95,
      "target": 100
    },
    {
      "key": "14813b3527d2fc53d812f3713550ad5e",
      "relation": "hasVariant",
      "source": 95,
      "target": 98
    },
    {
      "key": "68a0a25cd42693f2ce524188531fafa9",
      "relation": "hasVariant",
      "source": 95,
      "target": 99
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Interestingly, it was recently found that reducing the levels of Akt, another client of the Hsp90/CHIP complex, facilitates tau degradation [123], suggesting a synchronized balance between competing Hsp90 substrates that may be driven, in part, by their relative abundance or susceptibility to Hsp90 binding",
      "key": "b25e81d027218bd27827ec37afd25ac8",
      "line": 427,
      "relation": "negativeCorrelation",
      "source": 95,
      "subject": {
        "modifier": "Degradation"
      },
      "target": 84
    },
    {
      "key": "50ca1958ddc7fac01b57022c0f76bfcf",
      "relation": "partOf",
      "source": 95,
      "target": 71
    },
    {
      "key": "5f11fa2a0adfd47ca55180278500dc7d",
      "relation": "partOf",
      "source": 95,
      "target": 73
    },
    {
      "key": "5ca30cccc695fc10072e3879e21516b8",
      "relation": "partOf",
      "source": 95,
      "target": 67
    },
    {
      "key": "e2db2898586010f0aa2d1d4ec1efba00",
      "relation": "partOf",
      "source": 95,
      "target": 74
    },
    {
      "key": "c87fe9528120c1b77f4f101e9aec2b69",
      "relation": "partOf",
      "source": 95,
      "target": 59
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Phosphorylation of tau by the kinases GSK3b, Cdk5 and MARK2 is a major regulator of its microtubule interactions",
      "key": "b6e86d3efb9beec55228ba30f54bb812",
      "line": 98,
      "relation": "directlyIncreases",
      "source": 88,
      "subject": {
        "modifier": "Activity"
      },
      "target": 97
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Importantly, MARK2-based phosphorylation of tau is accelerated by the priming activity of either Cdk5 or GSK3b [29], suggesting that tau phosphorylation involves a series of ordered kinase events.",
      "key": "009ce6e9ad029ecdf49e2ba843ba8bdd",
      "line": 109,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 88,
      "target": 101
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Phosphorylation of tau by the kinases GSK3b, Cdk5 and MARK2 is a major regulator of its microtubule interactions",
      "key": "2baa23921ec4b792a437ae43d0f57ca3",
      "line": 99,
      "relation": "directlyIncreases",
      "source": 101,
      "subject": {
        "modifier": "Activity"
      },
      "target": 97
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Importantly, MARK2-based phosphorylation of tau is accelerated by the priming activity of either Cdk5 or GSK3b [29], suggesting that tau phosphorylation involves a series of ordered kinase events.",
      "key": "71256c3d8ff9a3006dd9cf1ddc262a2d",
      "line": 107,
      "relation": "directlyIncreases",
      "source": 101,
      "subject": {
        "modifier": "Activity"
      },
      "target": 97
    },
    {
      "key": "927477822675564e953e78c2bcccd4b9",
      "relation": "partOf",
      "source": 23,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "In general, phosphorylation of tau reduces its affinity for microtubules [30], while dephosphorylation via enzymes such as PP2A and PP5 restores binding",
      "key": "75f26d46f3333472b2b748d620380c8c",
      "line": 118,
      "relation": "decreases",
      "source": 103,
      "target": 97
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "In general, phosphorylation of tau reduces its affinity for microtubules [30], while dephosphorylation via enzymes such as PP2A and PP5 restores binding",
      "key": "2153dbf5a898100a0abbf4aa79920fe8",
      "line": 120,
      "relation": "increases",
      "source": 103,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "In general, phosphorylation of tau reduces its affinity for microtubules [30], while dephosphorylation via enzymes such as PP2A and PP5 restores binding",
      "key": "1f0d823e46065f2ef5c15066d948cddf",
      "line": 119,
      "relation": "decreases",
      "source": 102,
      "target": 97
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "In general, phosphorylation of tau reduces its affinity for microtubules [30], while dephosphorylation via enzymes such as PP2A and PP5 restores binding",
      "key": "690d20715c1e02e1494245ad8d1587c4",
      "line": 121,
      "relation": "increases",
      "source": 102,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "However, hyperphosphorylated forms of tau are more prone to aggregate, which might decrease their solubility and remove them from normal cycling",
      "key": "c2ee41d23e432fc9fa6666394c179b56",
      "line": 128,
      "relation": "increases",
      "source": 96,
      "target": 22
    },
    {
      "key": "886c28059f958a9c49962953412bef20",
      "relation": "partOf",
      "source": 96,
      "target": 75
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "There are no cures for any tauopathy. Neuroprotective agents, such as acetylcholinesterase inhibitors and NMDA antagonists, have been approved for use in the clinic, based on their ability to slow the rate of cognitive decline in patients with moderate to severe AD (reviewed in [36])",
      "key": "f395ebf7eabce7a337c26e30e4c989c7",
      "line": 139,
      "relation": "positiveCorrelation",
      "source": 33,
      "target": 51
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "There are no cures for any tauopathy. Neuroprotective agents, such as acetylcholinesterase inhibitors and NMDA antagonists, have been approved for use in the clinic, based on their ability to slow the rate of cognitive decline in patients with moderate to severe AD (reviewed in [36])",
      "key": "310b0a4b7aa1c7e7c63a615f94a2581a",
      "line": 140,
      "relation": "positiveCorrelation",
      "source": 1,
      "target": 51
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "These efforts have produced early-stage molecules of multiple different chemical classes, including rhodanine-based inhibitors, phenylthiazolylhydrazides, N-phenylamines, anthraquinones, benzothiazoles, phenothiazines and polyphenols [41]",
      "key": "071dbb8d016c85ba94c22fb0bf27a6ae",
      "line": 151,
      "relation": "increases",
      "source": 18,
      "target": 22
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "These efforts have produced early-stage molecules of multiple different chemical classes, including rhodanine-based inhibitors, phenylthiazolylhydrazides, N-phenylamines, anthraquinones, benzothiazoles, phenothiazines and polyphenols [41]",
      "key": "d1e83e9045065c93c15470a388596b04",
      "line": 152,
      "relation": "decreases",
      "source": 21,
      "target": 22
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "These efforts have produced early-stage molecules of multiple different chemical classes, including rhodanine-based inhibitors, phenylthiazolylhydrazides, N-phenylamines, anthraquinones, benzothiazoles, phenothiazines and polyphenols [41]",
      "key": "990066f821d4356bd6ed40c1ccea81b8",
      "line": 153,
      "relation": "decreases",
      "source": 36,
      "target": 22
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "These efforts have produced early-stage molecules of multiple different chemical classes, including rhodanine-based inhibitors, phenylthiazolylhydrazides, N-phenylamines, anthraquinones, benzothiazoles, phenothiazines and polyphenols [41]",
      "key": "6843e9187074bdd187889b29cc2e6082",
      "line": 154,
      "relation": "decreases",
      "source": 8,
      "target": 22
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "These efforts have produced early-stage molecules of multiple different chemical classes, including rhodanine-based inhibitors, phenylthiazolylhydrazides, N-phenylamines, anthraquinones, benzothiazoles, phenothiazines and polyphenols [41]",
      "key": "7bac76264425a972ccf53051d46e787a",
      "line": 155,
      "relation": "decreases",
      "source": 9,
      "target": 22
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "These efforts have produced early-stage molecules of multiple different chemical classes, including rhodanine-based inhibitors, phenylthiazolylhydrazides, N-phenylamines, anthraquinones, benzothiazoles, phenothiazines and polyphenols [41]",
      "key": "224c845b57b7d9fbdcd7573cc7f8d1bb",
      "line": 156,
      "relation": "decreases",
      "source": 13,
      "target": 22
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "These efforts have produced early-stage molecules of multiple different chemical classes, including rhodanine-based inhibitors, phenylthiazolylhydrazides, N-phenylamines, anthraquinones, benzothiazoles, phenothiazines and polyphenols [41]",
      "key": "4438ae14f1b659ba3f333eca768de3f1",
      "line": 157,
      "relation": "decreases",
      "source": 16,
      "target": 22
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Using high-throughput screening against the J-protein-stimulated ATPase activity of an Hsp70, we also found polyphenols that selectively block J-stimulated activities by interfering with J-protein recruitment to the Hsp70 complex [72].",
      "key": "f902fbbd2277d60c52b257308cfb506e",
      "line": 615,
      "relation": "decreases",
      "source": 16,
      "target": 81
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "All proteins, including tau, are subject to extensive regulation by the cellular quality control pathways, which carefully control the balance between protein expression and turnover to maintain healthy protein homeostasis (or proteostasis)",
      "key": "5974c5c814fcf35b6a5e13b04c34b055",
      "line": 166,
      "relation": "regulates",
      "source": 40,
      "target": 95
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "All proteins, including tau, are subject to extensive regulation by the cellular quality control pathways, which carefully control the balance between protein expression and turnover to maintain healthy protein homeostasis (or proteostasis)",
      "key": "92a7098f2a4180d38d8515dcc2e387e6",
      "line": 167,
      "relation": "regulates",
      "source": 40,
      "target": 31
    },
    {
      "key": "286c327e6883ded17a7e086f40cc98e0",
      "relation": "partOf",
      "source": 31,
      "target": 62
    },
    {
      "key": "220e4b963a8e7485f8ee54e364425735",
      "relation": "partOf",
      "source": 31,
      "target": 61
    },
    {
      "key": "a0c1ae25b9800c31f50d9f0d94d01682",
      "relation": "partOf",
      "source": 31,
      "target": 60
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Brain": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Interestingly, tau clearance is known to be impaired in the aging brain [45], supporting the idea that diminished quality control might be conducive to certain tauopathies, such as AD, which are linked to aging",
      "key": "bde37ae1ed9582592008c661f682206a",
      "line": 177,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "negativeCorrelation",
      "source": 49,
      "target": 95
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "In relation to tau biology, FKBP51 enhances the association of Hsp90 with tau, co-localizes with tau in murine neurons, coimmunoprecipitates with tau in AD tissue samples and increases with age in an AD mouse model [136].",
      "key": "7c7fe0aa52996d45fd3f3aadef19cee4",
      "line": 514,
      "relation": "positiveCorrelation",
      "source": 49,
      "target": 89
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Furthermore, recent evidence suggests that tau is essential for the neurotoxicity of amyloid-b, providing a possible link between these classic AD targets and suggesting that reductions in tau levels might be important via multiple, beneficial mechanisms [46–48]",
      "key": "f8b33c700163d35f9cdb09da153bc1a7",
      "line": 186,
      "relation": "increases",
      "source": 2,
      "target": 114
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Molecular chaperones are abundant and highly conserved proteins that assume an important role in protein quality control",
      "key": "d205bfc849dd2dd0c553f06b9bb65b3c",
      "line": 193,
      "relation": "association",
      "source": 27,
      "target": 47
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Molecular chaperones are abundant and highly conserved proteins that assume an important role in protein quality control",
      "key": "1876e128916e27f87a0e5cb356e2f50e",
      "line": 193,
      "relation": "association",
      "source": 47,
      "target": 27
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "However, under potentially proteotoxic conditions, the post-translational modifications or mutations that damage tau’s affinity for microtubules and favor its aggregation are thought to generate a molecular ‘danger signal’ that specifically alerts the quality control system [112,113].",
      "key": "480ba94d07226bf27364b24637423813",
      "line": 371,
      "relation": "association",
      "source": 47,
      "target": 100
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Several members of the chaperone family are upregulated in response to stress and, thus, these factors have been termed heat shock proteins (Hsps)",
      "key": "dc9d0c4f53095613c10468b2ed8dfffb",
      "line": 199,
      "relation": "increases",
      "source": 41,
      "target": 26
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "These proteins are ATP-independent chaperones that undergo homo-oligomerization in response to stress [97,98]",
      "key": "a66394c48a3275c0514fcf46083a3d85",
      "line": 311,
      "relation": "increases",
      "source": 41,
      "target": 20
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Importantly, the Hsps are also critical at the end of a protein’s life, as they facilitate turnover by the proteasome system and the clearance of proteotoxic aggregates by autophagy [53]",
      "key": "577cb1e43a7baf8799d33ad8b508e1e2",
      "line": 214,
      "relation": "increases",
      "source": 26,
      "target": 44
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Importantly, the Hsps are also critical at the end of a protein’s life, as they facilitate turnover by the proteasome system and the clearance of proteotoxic aggregates by autophagy [53]",
      "key": "5c495ac74bc37a5af1c167703d915061",
      "line": 215,
      "relation": "increases",
      "source": 26,
      "target": 50
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "The expression of Hsps is regulated by heat shock factor 1 (HSF1), which, under stress conditions, becomes associated with heat shock elements to elevate the transcription of Hsps and other proteins [51].",
      "key": "248d09baaaf47ff7b9e279a6f366117c",
      "line": 207,
      "relation": "increases",
      "source": 91,
      "target": 26
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "However, the mechanisms that link HSF1 induction to improved proteostasis are not yet clear",
      "key": "341551a2872e113bb0ebdcfaf47fcf51",
      "line": 621,
      "relation": "increases",
      "source": 91,
      "target": 40
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "The intrinsic ATPase activity of Hsp70 is very weak (~0.2 nmol/μg/min) [60] and, under physiological conditions, it is regulated by cochaperones, including J-proteins and nucleotide exchange factors (NEFs).",
      "key": "5789236b237beb5db8db58e217bab103",
      "line": 223,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 109,
      "target": 111
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Briefly, J-proteins cause a conformational change in Hsp70s that accelerates ATP hydrolysis [61], while NEFs facilitate ADP release [62]",
      "key": "3d9f2502dbd99adf45486741cb43cab3",
      "line": 231,
      "relation": "increases",
      "source": 109,
      "target": 118
    },
    {
      "key": "a41cf510ff7d0d54c9f3036c9553e17c",
      "relation": "partOf",
      "source": 109,
      "target": 81
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "During protein quality control, Hsp70, Hsp90 and Hsp27 (and their co-chaperones) often work in concert. If prolonged misfolding is detected, the chaperones shuttle the protein to a degradation endpoint, such as the proteasome or autophagy",
      "key": "dd67e5e9fb7feef6dd544f2ea45e1cf3",
      "line": 324,
      "relation": "increases",
      "source": 111,
      "target": 47
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "During protein quality control, Hsp70, Hsp90 and Hsp27 (and their co-chaperones) often work in concert. If prolonged misfolding is detected, the chaperones shuttle the protein to a degradation endpoint, such as the proteasome or autophagy",
      "key": "264fbee49d2d0f6676f75d259fe07150",
      "line": 325,
      "relation": "increases",
      "source": 111,
      "target": 44
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "During protein quality control, Hsp70, Hsp90 and Hsp27 (and their co-chaperones) often work in concert. If prolonged misfolding is detected, the chaperones shuttle the protein to a degradation endpoint, such as the proteasome or autophagy",
      "key": "1ba14cd44c835b4fcb0131069040af43",
      "line": 326,
      "relation": "increases",
      "source": 111,
      "target": 50
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Alternatively, either Hsp70 or Hsp90 can recruit the ubiquitin E3 ligase, C-terminal Hsp70 interacting protein (CHIP), to degrade the bound substrate [104]",
      "key": "b018e4f44fdc47ec5299c42dcef772a1",
      "line": 338,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 111,
      "target": 106
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Although both Hsp70 and Hsp90 can promote degradation of client proteins, it has recently been shown that, functionally, the Hsp70 complex often dominates triage decisions [85,107,109]",
      "key": "0806a941052eeb707cc240a46339fe78",
      "line": 360,
      "relation": "increases",
      "source": 111,
      "target": 45
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Hsp70 has been shown to both stabilize binding of tau to microtubules [114] and promote its degradation in combination with CHIP [115,116]",
      "key": "11768f3ca409aaf1ac3d6f9577901fe8",
      "line": 377,
      "relation": "increases",
      "source": 111,
      "target": 56
    },
    {
      "key": "955837c8f3952c8afb0a087e101ba6af",
      "relation": "partOf",
      "source": 111,
      "target": 79
    },
    {
      "annotations": {
        "Confidence": {
          "Low": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "In fact, recent work from our group has shown that inhibition of the ATPase activity of Hsp70/Hsc70 promotes proteasomal degradation of tau; whereas activation results in tau accumulation [117]",
      "key": "ae81d3f70736be74a40f1add372b8060",
      "line": 391,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "decreases",
      "source": 111,
      "subject": {
        "effect": {
          "name": "ATPase activity",
          "namespace": "GO"
        },
        "modifier": "Activity"
      },
      "target": 95
    },
    {
      "annotations": {
        "Confidence": {
          "Low": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "In fact, recent work from our group has shown that inhibition of the ATPase activity of Hsp70/Hsc70 promotes proteasomal degradation of tau; whereas activation results in tau accumulation [117]",
      "key": "d807f632e8f3f0ff63823a0ae10ab354",
      "line": 393,
      "relation": "increases",
      "source": 111,
      "subject": {
        "modifier": "Activity"
      },
      "target": 95
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "The fact that Hsp70 inhibitors reduce tau levels without affecting other likely Hsp70 substrates, such as a-synuclein or TDP-43, generally supports the idea that substrates are actively involved in dictating their own fate [117]",
      "key": "a590eee30977db08ec69cfdba392149e",
      "line": 559,
      "relation": "increases",
      "source": 111,
      "subject": {
        "modifier": "Activity"
      },
      "target": 95
    },
    {
      "key": "9dad1af3289634c72e13e8a96ad043f9",
      "relation": "partOf",
      "source": 111,
      "target": 72
    },
    {
      "key": "b2f3782af35801a7efadb71f3a4a03ed",
      "relation": "partOf",
      "source": 111,
      "target": 73
    },
    {
      "key": "44abd559a14318653f679509b294370e",
      "relation": "partOf",
      "source": 111,
      "target": 62
    },
    {
      "key": "589e3e9bd35149431c44557599ac40e2",
      "relation": "partOf",
      "source": 111,
      "target": 61
    },
    {
      "key": "5917211a57f66081c3d9e8b87239349d",
      "relation": "partOf",
      "source": 111,
      "target": 80
    },
    {
      "key": "8ec75dc8f1ff95add5845b1ec530238b",
      "relation": "partOf",
      "source": 111,
      "target": 81
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "The intrinsic ATPase activity of Hsp70 is very weak (~0.2 nmol/μg/min) [60] and, under physiological conditions, it is regulated by cochaperones, including J-proteins and nucleotide exchange factors (NEFs).",
      "key": "187b75f2c840ef6b0cef4522eff5f23e",
      "line": 224,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 25,
      "target": 111
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Briefly, J-proteins cause a conformational change in Hsp70s that accelerates ATP hydrolysis [61], while NEFs facilitate ADP release [62]",
      "key": "06b5d8965de726d5d757570374e47349",
      "line": 232,
      "relation": "increases",
      "source": 25,
      "target": 5
    },
    {
      "key": "16957e9134ce9403849c1f00e455043e",
      "relation": "hasReactant",
      "source": 118,
      "target": 6
    },
    {
      "key": "9f88c6f577f9627631b6ce253f0536e8",
      "relation": "hasProduct",
      "source": 118,
      "target": 4
    },
    {
      "key": "7dc0c3f7f85ecfce9f284574e38481ac",
      "relation": "hasProduct",
      "source": 118,
      "target": 5
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "For example, VER-155008 is an ATP-competitive compound developed by structure-guided design [69,70]",
      "key": "5aa72a32362d9641aabf2e0322e61067",
      "line": 239,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 34,
      "target": 24
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "As might be expected given the diverse mechanisms of these compounds, known Hsp70 inhibitors represent a variety of chemical classes, including dihydropyrimidines, adenosine analogs, polyamines and others (Figure 1) [52,63]. Moreover, many of these inhibitors, including methylene blue and MKT-077, have poorly understood mechanisms",
      "key": "0a0d4445854bab7dec6398aaa46a7cd8",
      "line": 248,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 32,
      "target": 111
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "For example, we found that dihydropyrimidine-based molecules can either force the association of a prokaryotic Hsp70 with its J-protein partner or, with a relatively modest change in chemical structure, related compounds could block this contact [73].",
      "key": "e9cc2aec9e00a233ea4c48d822b8b8cd",
      "line": 608,
      "relation": "regulates",
      "source": 32,
      "target": 81
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "As might be expected given the diverse mechanisms of these compounds, known Hsp70 inhibitors represent a variety of chemical classes, including dihydropyrimidines, adenosine analogs, polyamines and others (Figure 1) [52,63]. Moreover, many of these inhibitors, including methylene blue and MKT-077, have poorly understood mechanisms",
      "key": "ebbf1c45bb5a7f3eb98e5f17be64e168",
      "line": 249,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 7,
      "target": 111
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "As might be expected given the diverse mechanisms of these compounds, known Hsp70 inhibitors represent a variety of chemical classes, including dihydropyrimidines, adenosine analogs, polyamines and others (Figure 1) [52,63]. Moreover, many of these inhibitors, including methylene blue and MKT-077, have poorly understood mechanisms",
      "key": "964f89029b7bad853d99c5d397ee707a",
      "line": 250,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 14,
      "target": 111
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "As might be expected given the diverse mechanisms of these compounds, known Hsp70 inhibitors represent a variety of chemical classes, including dihydropyrimidines, adenosine analogs, polyamines and others (Figure 1) [52,63]. Moreover, many of these inhibitors, including methylene blue and MKT-077, have poorly understood mechanisms",
      "key": "a0a59117cbd436dc5cb4adb736d2ee79",
      "line": 251,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 3,
      "target": 111
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "As might be expected given the diverse mechanisms of these compounds, known Hsp70 inhibitors represent a variety of chemical classes, including dihydropyrimidines, adenosine analogs, polyamines and others (Figure 1) [52,63]. Moreover, many of these inhibitors, including methylene blue and MKT-077, have poorly understood mechanisms",
      "key": "29f1d2391d0e7e9a3bbaffe239caff6d",
      "line": 252,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 37,
      "target": 111
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Recent structural studies have suggested that Hsp90 functions as a homodimer in which the C-terminal domains of two Hsp90 molecules are in contact at the bottom of the ‘V-shaped’ open conformer",
      "key": "4e256de6aca90277160204b7dc602697",
      "line": 258,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 65,
      "target": 82
    },
    {
      "key": "b5db22c081b24af94a4206c835eb8d0f",
      "relation": "partOf",
      "source": 82,
      "target": 65
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "More recently, there has also been interest in developing compounds, such as celastrol (Figure 1), that selectively disrupt association of co-chaperones with Hsp90 as an alternative way to control chaperone activity [93–96].",
      "key": "e791f2d140e5a9026de888f5d832b134",
      "line": 304,
      "relation": "association",
      "source": 82,
      "subject": {
        "modifier": "Activity"
      },
      "target": 10
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "During protein quality control, Hsp70, Hsp90 and Hsp27 (and their co-chaperones) often work in concert. If prolonged misfolding is detected, the chaperones shuttle the protein to a degradation endpoint, such as the proteasome or autophagy",
      "key": "fed667078b5d62e9a57cb53443a4841f",
      "line": 327,
      "relation": "increases",
      "source": 82,
      "target": 47
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "During protein quality control, Hsp70, Hsp90 and Hsp27 (and their co-chaperones) often work in concert. If prolonged misfolding is detected, the chaperones shuttle the protein to a degradation endpoint, such as the proteasome or autophagy",
      "key": "d8c080449161e78b31a370ff5cd1da51",
      "line": 328,
      "relation": "increases",
      "source": 82,
      "target": 44
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "During protein quality control, Hsp70, Hsp90 and Hsp27 (and their co-chaperones) often work in concert. If prolonged misfolding is detected, the chaperones shuttle the protein to a degradation endpoint, such as the proteasome or autophagy",
      "key": "b9b80b7b52f5c6089fc61d4c6e4835f8",
      "line": 329,
      "relation": "increases",
      "source": 82,
      "target": 50
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Alternatively, either Hsp70 or Hsp90 can recruit the ubiquitin E3 ligase, C-terminal Hsp70 interacting protein (CHIP), to degrade the bound substrate [104]",
      "key": "75151f1dc4fdbd0326e9005aa033cc41",
      "line": 339,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 82,
      "target": 106
    },
    {
      "key": "5b480ba832f4fd2009a3ca4d6aae4702",
      "relation": "partOf",
      "source": 82,
      "target": 58
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Although both Hsp70 and Hsp90 can promote degradation of client proteins, it has recently been shown that, functionally, the Hsp70 complex often dominates triage decisions [85,107,109]",
      "key": "973f01547d63572da0e0d58fddb9cee9",
      "line": 361,
      "relation": "increases",
      "source": 82,
      "target": 45
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Hsp90 was also shown to increase association of tau with microtubules [114]; however, its binding is not well characterized and it is not known whether this is a direct or indirect process",
      "key": "6419a42200ce53f0f3c4172df3168ffa",
      "line": 400,
      "relation": "increases",
      "source": 82,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "For example, it has recently been shown that Hsp90 promotes tau’s phosphorylation by its ability to stabilize GSK3b [118]",
      "key": "9fcf9d0dbb4ad99d411864a89afaacee",
      "line": 406,
      "relation": "increases",
      "source": 82,
      "target": 97
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Together, multiple studies suggest that Hsp90 regulates the stability of both phospho- and mutant-tau",
      "key": "e57cd5f53a5b7b2b35c031cc71c9bd9d",
      "line": 433,
      "relation": "regulates",
      "source": 82,
      "target": 97
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "For example, it has recently been shown that Hsp90 promotes tau’s phosphorylation by its ability to stabilize GSK3b [118]",
      "key": "83c0579b49bfc6eb03a6afd2a40d599f",
      "line": 407,
      "object": {
        "modifier": "Activity"
      },
      "relation": "regulates",
      "source": 82,
      "target": 90
    },
    {
      "key": "0e1749807bfe804f89e753f7876e091e",
      "relation": "partOf",
      "source": 82,
      "target": 69
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Together, multiple studies suggest that Hsp90 regulates the stability of both phospho- and mutant-tau",
      "key": "d010dda0abdfaaa9a7f4d48c6a5bd416",
      "line": 434,
      "relation": "regulates",
      "source": 82,
      "target": 100
    },
    {
      "key": "724c3cceba581216864cb582f1808483",
      "relation": "partOf",
      "source": 82,
      "target": 67
    },
    {
      "key": "cdf86d59960a30100fdb0723346f92a1",
      "relation": "partOf",
      "source": 82,
      "target": 66
    },
    {
      "key": "877c8de90d7789527709c1f218c61867",
      "relation": "partOf",
      "source": 82,
      "target": 60
    },
    {
      "key": "35cd7bdc346231315fcd9e8e274f239f",
      "relation": "partOf",
      "source": 82,
      "target": 68
    },
    {
      "key": "a0987b6cd844c831916bb6cdf845406f",
      "relation": "partOf",
      "source": 82,
      "target": 70
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "As in the case of Hsp70, cochaperones of Hsp90, such as Aha1, cdc37 and TPR domain-containing proteins, regulate its ATPase activity and control its conformational transitions (reviewed in [84]).",
      "key": "1b044686e29eb27e6208229e8aa9e793",
      "line": 265,
      "object": {
        "effect": {
          "name": "ATPase activity",
          "namespace": "GO"
        },
        "modifier": "Activity"
      },
      "relation": "regulates",
      "source": 83,
      "target": 82
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "In addition, Hsp90’s hydrolysis of ATP, which is stimulated by Aha1, facilitates polypeptide release [82,106] and transfer to CHIP or other E3 ligases [107,108]",
      "key": "abe4670f4e906b45e7c71289bbcba43b",
      "line": 353,
      "relation": "increases",
      "source": 83,
      "target": 118
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "In addition, Hsp90’s hydrolysis of ATP, which is stimulated by Aha1, facilitates polypeptide release [82,106] and transfer to CHIP or other E3 ligases [107,108]",
      "key": "013eda99bc8afd8bcef95e32ddd53fa7",
      "line": 354,
      "relation": "increases",
      "source": 83,
      "target": 54
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "As in the case of Hsp70, cochaperones of Hsp90, such as Aha1, cdc37 and TPR domain-containing proteins, regulate its ATPase activity and control its conformational transitions (reviewed in [84]).",
      "key": "ca4d20a42ee53df245209989b024ddbc",
      "line": 266,
      "object": {
        "effect": {
          "name": "ATPase activity",
          "namespace": "GO"
        },
        "modifier": "Activity"
      },
      "relation": "regulates",
      "source": 87,
      "target": 82
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "For example, the co-chaperones cdc37, a peptidyl-prolyl cis-trans isomerase (PPIase) family member, and p23 are all critical for the transfer of kinases to Hsp90 and maturation of the active protein [76,105]",
      "key": "60562e3e9e275c02e9f00e9f0d06e502",
      "line": 346,
      "relation": "increases",
      "source": 87,
      "target": 58
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "As in the case of Hsp70, cochaperones of Hsp90, such as Aha1, cdc37 and TPR domain-containing proteins, regulate its ATPase activity and control its conformational transitions (reviewed in [84]).",
      "key": "b718ac32259de7b81addb99f19275f0b",
      "line": 267,
      "object": {
        "effect": {
          "name": "ATPase activity",
          "namespace": "GO"
        },
        "modifier": "Activity"
      },
      "relation": "regulates",
      "source": 113,
      "target": 82
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Work on Hsp90 inhibitors benefited from the early discovery of the natural product, geldanamycin, which competes with ATP and induces destabilization of Hsp90-bound proteins [87]",
      "key": "a595d5dbd0f699dbe1ebdf7456ba70be",
      "line": 273,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 11,
      "target": 82
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "For example, the Hsp90 inhibitor geldanamycin mimics ADP binding, but also inhibits recruitment of p23, which is a necessary step in client maturation [145].",
      "key": "ba9787cac9b554e7407a7d765dbd203d",
      "line": 574,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 11,
      "target": 82
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "For example, the Hsp90 inhibitor geldanamycin mimics ADP binding, but also inhibits recruitment of p23, which is a necessary step in client maturation [145].",
      "key": "adf4e783e77cf7f6c2ad9014e37e3633",
      "line": 575,
      "relation": "decreases",
      "source": 11,
      "target": 68
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Since this discovery, a number of high-affinity analogs, such as 17-AAG, and alternative synthetic scaffolds, including radicicol and PU-H71, have been reported (Figure 1) [85,88]. These compounds bind in either the N-terminal ATP-binding site (e.g., 17-AAG, radicicol and PU-H71) [89] or C-terminal dimerization domain (e.g., novobiocin and A4) [90,91], and they show great promise as both anticancer compounds and research tools for understanding Hsp90 biology",
      "key": "bdc1d69e26b3a3bb0969f714ac38dab2",
      "line": 283,
      "relation": "directlyIncreases",
      "source": 38,
      "target": 64
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Since this discovery, a number of high-affinity analogs, such as 17-AAG, and alternative synthetic scaffolds, including radicicol and PU-H71, have been reported (Figure 1) [85,88]. These compounds bind in either the N-terminal ATP-binding site (e.g., 17-AAG, radicicol and PU-H71) [89] or C-terminal dimerization domain (e.g., novobiocin and A4) [90,91], and they show great promise as both anticancer compounds and research tools for understanding Hsp90 biology",
      "key": "6800fddc13e7f718260767f02e368418",
      "line": 284,
      "object": {
        "modifier": "Activity"
      },
      "relation": "directlyDecreases",
      "source": 38,
      "target": 82
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Since this discovery, a number of high-affinity analogs, such as 17-AAG, and alternative synthetic scaffolds, including radicicol and PU-H71, have been reported (Figure 1) [85,88]. These compounds bind in either the N-terminal ATP-binding site (e.g., 17-AAG, radicicol and PU-H71) [89] or C-terminal dimerization domain (e.g., novobiocin and A4) [90,91], and they show great promise as both anticancer compounds and research tools for understanding Hsp90 biology",
      "key": "d697baede9188de4b1ff60609dd2d1e9",
      "line": 293,
      "relation": "decreases",
      "source": 38,
      "target": 116
    },
    {
      "key": "225c74b4193543a7e252945859740fb1",
      "relation": "partOf",
      "source": 39,
      "target": 64
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Since this discovery, a number of high-affinity analogs, such as 17-AAG, and alternative synthetic scaffolds, including radicicol and PU-H71, have been reported (Figure 1) [85,88]. These compounds bind in either the N-terminal ATP-binding site (e.g., 17-AAG, radicicol and PU-H71) [89] or C-terminal dimerization domain (e.g., novobiocin and A4) [90,91], and they show great promise as both anticancer compounds and research tools for understanding Hsp90 biology",
      "key": "d15ab10d4379ab2b45c6f3f5e347b47b",
      "line": 287,
      "relation": "directlyIncreases",
      "source": 39,
      "target": 64
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Since this discovery, a number of high-affinity analogs, such as 17-AAG, and alternative synthetic scaffolds, including radicicol and PU-H71, have been reported (Figure 1) [85,88]. These compounds bind in either the N-terminal ATP-binding site (e.g., 17-AAG, radicicol and PU-H71) [89] or C-terminal dimerization domain (e.g., novobiocin and A4) [90,91], and they show great promise as both anticancer compounds and research tools for understanding Hsp90 biology",
      "key": "c892e56998be4b395430c65ec2650938",
      "line": 288,
      "object": {
        "modifier": "Activity"
      },
      "relation": "directlyDecreases",
      "source": 39,
      "target": 82
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Since this discovery, a number of high-affinity analogs, such as 17-AAG, and alternative synthetic scaffolds, including radicicol and PU-H71, have been reported (Figure 1) [85,88]. These compounds bind in either the N-terminal ATP-binding site (e.g., 17-AAG, radicicol and PU-H71) [89] or C-terminal dimerization domain (e.g., novobiocin and A4) [90,91], and they show great promise as both anticancer compounds and research tools for understanding Hsp90 biology",
      "key": "ff1408a5318eef5dc2308959871b0f48",
      "line": 295,
      "relation": "decreases",
      "source": 39,
      "target": 116
    },
    {
      "key": "f49057e44447988482e971d715b2737d",
      "relation": "partOf",
      "source": 112,
      "target": 64
    },
    {
      "key": "9394309df6e5c06cf838ad506b635ad2",
      "relation": "partOf",
      "source": 112,
      "target": 55
    },
    {
      "key": "d8785af02c0c6e1e0824b94b08a9b405",
      "relation": "partOf",
      "source": 17,
      "target": 55
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Since this discovery, a number of high-affinity analogs, such as 17-AAG, and alternative synthetic scaffolds, including radicicol and PU-H71, have been reported (Figure 1) [85,88]. These compounds bind in either the N-terminal ATP-binding site (e.g., 17-AAG, radicicol and PU-H71) [89] or C-terminal dimerization domain (e.g., novobiocin and A4) [90,91], and they show great promise as both anticancer compounds and research tools for understanding Hsp90 biology",
      "key": "e7867e1983c324e562d697b64e51f5f0",
      "line": 285,
      "relation": "directlyIncreases",
      "source": 17,
      "target": 55
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Since this discovery, a number of high-affinity analogs, such as 17-AAG, and alternative synthetic scaffolds, including radicicol and PU-H71, have been reported (Figure 1) [85,88]. These compounds bind in either the N-terminal ATP-binding site (e.g., 17-AAG, radicicol and PU-H71) [89] or C-terminal dimerization domain (e.g., novobiocin and A4) [90,91], and they show great promise as both anticancer compounds and research tools for understanding Hsp90 biology",
      "key": "1c05a30386bdd4b43bc0061972a975fd",
      "line": 286,
      "object": {
        "modifier": "Activity"
      },
      "relation": "directlyDecreases",
      "source": 17,
      "target": 82
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Since this discovery, a number of high-affinity analogs, such as 17-AAG, and alternative synthetic scaffolds, including radicicol and PU-H71, have been reported (Figure 1) [85,88]. These compounds bind in either the N-terminal ATP-binding site (e.g., 17-AAG, radicicol and PU-H71) [89] or C-terminal dimerization domain (e.g., novobiocin and A4) [90,91], and they show great promise as both anticancer compounds and research tools for understanding Hsp90 biology",
      "key": "4b1b244e27713d7e67100d6559efe81b",
      "line": 294,
      "relation": "decreases",
      "source": 17,
      "target": 116
    },
    {
      "key": "0a0e4c2f73d022068029ae4c4f444a20",
      "relation": "partOf",
      "source": 12,
      "target": 53
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Since this discovery, a number of high-affinity analogs, such as 17-AAG, and alternative synthetic scaffolds, including radicicol and PU-H71, have been reported (Figure 1) [85,88]. These compounds bind in either the N-terminal ATP-binding site (e.g., 17-AAG, radicicol and PU-H71) [89] or C-terminal dimerization domain (e.g., novobiocin and A4) [90,91], and they show great promise as both anticancer compounds and research tools for understanding Hsp90 biology",
      "key": "fbe705f8a3f8a45df36fd646139d837d",
      "line": 289,
      "relation": "directlyIncreases",
      "source": 12,
      "target": 53
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Since this discovery, a number of high-affinity analogs, such as 17-AAG, and alternative synthetic scaffolds, including radicicol and PU-H71, have been reported (Figure 1) [85,88]. These compounds bind in either the N-terminal ATP-binding site (e.g., 17-AAG, radicicol and PU-H71) [89] or C-terminal dimerization domain (e.g., novobiocin and A4) [90,91], and they show great promise as both anticancer compounds and research tools for understanding Hsp90 biology",
      "key": "74249e931c66ed80ed89e3b1072123af",
      "line": 290,
      "object": {
        "modifier": "Activity"
      },
      "relation": "directlyDecreases",
      "source": 12,
      "target": 82
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Since this discovery, a number of high-affinity analogs, such as 17-AAG, and alternative synthetic scaffolds, including radicicol and PU-H71, have been reported (Figure 1) [85,88]. These compounds bind in either the N-terminal ATP-binding site (e.g., 17-AAG, radicicol and PU-H71) [89] or C-terminal dimerization domain (e.g., novobiocin and A4) [90,91], and they show great promise as both anticancer compounds and research tools for understanding Hsp90 biology",
      "key": "5816301c5bf55849be942d90d865424c",
      "line": 296,
      "relation": "decreases",
      "source": 12,
      "target": 116
    },
    {
      "key": "751c97ac38fc3c5e36c53d60bca207c3",
      "relation": "partOf",
      "source": 110,
      "target": 53
    },
    {
      "key": "9f07c05db04d59bb0f576dec0f5a22b9",
      "relation": "partOf",
      "source": 110,
      "target": 63
    },
    {
      "key": "d3fc55b52e573a599c8e05f20f530809",
      "relation": "partOf",
      "source": 35,
      "target": 63
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Since this discovery, a number of high-affinity analogs, such as 17-AAG, and alternative synthetic scaffolds, including radicicol and PU-H71, have been reported (Figure 1) [85,88]. These compounds bind in either the N-terminal ATP-binding site (e.g., 17-AAG, radicicol and PU-H71) [89] or C-terminal dimerization domain (e.g., novobiocin and A4) [90,91], and they show great promise as both anticancer compounds and research tools for understanding Hsp90 biology",
      "key": "edc39beb4f01073dedb14803c44f633a",
      "line": 291,
      "relation": "directlyIncreases",
      "source": 35,
      "target": 63
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Since this discovery, a number of high-affinity analogs, such as 17-AAG, and alternative synthetic scaffolds, including radicicol and PU-H71, have been reported (Figure 1) [85,88]. These compounds bind in either the N-terminal ATP-binding site (e.g., 17-AAG, radicicol and PU-H71) [89] or C-terminal dimerization domain (e.g., novobiocin and A4) [90,91], and they show great promise as both anticancer compounds and research tools for understanding Hsp90 biology",
      "key": "f5697144cc97e722f2f74ec26638403a",
      "line": 292,
      "object": {
        "modifier": "Activity"
      },
      "relation": "directlyDecreases",
      "source": 35,
      "target": 82
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Since this discovery, a number of high-affinity analogs, such as 17-AAG, and alternative synthetic scaffolds, including radicicol and PU-H71, have been reported (Figure 1) [85,88]. These compounds bind in either the N-terminal ATP-binding site (e.g., 17-AAG, radicicol and PU-H71) [89] or C-terminal dimerization domain (e.g., novobiocin and A4) [90,91], and they show great promise as both anticancer compounds and research tools for understanding Hsp90 biology",
      "key": "a33a6c6a3dc46ec147eed68656ed1309",
      "line": 297,
      "relation": "decreases",
      "source": 35,
      "target": 116
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "More recently, there has also been interest in developing compounds, such as celastrol (Figure 1), that selectively disrupt association of co-chaperones with Hsp90 as an alternative way to control chaperone activity [93–96].",
      "key": "03b0ae908bb96710bd942b5d30b6738e",
      "line": 304,
      "object": {
        "modifier": "Activity"
      },
      "relation": "association",
      "source": 10,
      "target": 82
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "To allow substrate release, Hsp27 oligomerization is reversible; a process that is regulated, at least in part, by phosphorylation",
      "key": "e3e0700c27e34f2b2340fdca4d52b8ee",
      "line": 317,
      "relation": "regulates",
      "source": 52,
      "target": 20
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "During protein quality control, Hsp70, Hsp90 and Hsp27 (and their co-chaperones) often work in concert. If prolonged misfolding is detected, the chaperones shuttle the protein to a degradation endpoint, such as the proteasome or autophagy",
      "key": "358721b27b2442675c6f7a6a6a3c4c87",
      "line": 330,
      "relation": "increases",
      "source": 93,
      "target": 47
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "During protein quality control, Hsp70, Hsp90 and Hsp27 (and their co-chaperones) often work in concert. If prolonged misfolding is detected, the chaperones shuttle the protein to a degradation endpoint, such as the proteasome or autophagy",
      "key": "46a49137d471ceca0244982fa3ac51b7",
      "line": 331,
      "relation": "increases",
      "source": 93,
      "target": 44
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "During protein quality control, Hsp70, Hsp90 and Hsp27 (and their co-chaperones) often work in concert. If prolonged misfolding is detected, the chaperones shuttle the protein to a degradation endpoint, such as the proteasome or autophagy",
      "key": "21156dc035866eb8029cb3e20b7c7342",
      "line": 332,
      "relation": "increases",
      "source": 93,
      "target": 50
    },
    {
      "key": "bb14d809b3b6bb98ef68b26e3b9693a2",
      "relation": "partOf",
      "source": 93,
      "target": 75
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Hsp27 has emerged as a potential target for tau regulation based on early findings that it preferentially binds to phosphorylated and hyperphosphorylated tau and promotes their clearance [125,126]",
      "key": "23e9d196d86b5ed52bcc970f79d68f80",
      "line": 440,
      "relation": "directlyIncreases",
      "source": 93,
      "target": 75
    },
    {
      "key": "342c30fc01a9908723a955323000f05a",
      "relation": "partOf",
      "source": 93,
      "target": 76
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Hsp27 has emerged as a potential target for tau regulation based on early findings that it preferentially binds to phosphorylated and hyperphosphorylated tau and promotes their clearance [125,126]",
      "key": "788bd85ba1f006d625b4fa6255df67d5",
      "line": 441,
      "relation": "directlyIncreases",
      "source": 93,
      "target": 76
    },
    {
      "annotations": {
        "Cell": {
          "astrocyte": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "However, astrocyte-derived Hsp27 has been shown to promote tau accumulation and Hsp27 associates with tau tangles in a mouse model [127,128], suggesting a more complex relationship",
      "key": "7bf62a2ce4ffee4545be542c8fbe1d27",
      "line": 450,
      "relation": "increases",
      "source": 93,
      "target": 95
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Recently, our group demonstrated that viral delivery of wild-type Hsp27 into the brains of tau-transgenic mice reduced tau levels and rescued long-term potentiation deficits.",
      "key": "6a44f5144b6e71b5c1c8ff8a289911a2",
      "line": 461,
      "relation": "decreases",
      "source": 93,
      "target": 95
    },
    {
      "key": "d3909fe69073470ec65584b371ce8df9",
      "relation": "partOf",
      "source": 93,
      "target": 57
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "However, astrocyte-derived Hsp27 has been shown to promote tau accumulation and Hsp27 associates with tau tangles in a mouse model [127,128], suggesting a more complex relationship",
      "key": "32bb3903a2fcd4850ec734670bc608c7",
      "line": 453,
      "relation": "directlyIncreases",
      "source": 93,
      "target": 57
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Recently, our group demonstrated that viral delivery of wild-type Hsp27 into the brains of tau-transgenic mice reduced tau levels and rescued long-term potentiation deficits.",
      "key": "c09f0fae444938cd514ef23e05758c0c",
      "line": 462,
      "relation": "positiveCorrelation",
      "source": 93,
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Alternatively, either Hsp70 or Hsp90 can recruit the ubiquitin E3 ligase, C-terminal Hsp70 interacting protein (CHIP), to degrade the bound substrate [104]",
      "key": "c2902625216dca640e0b6f42c3d29d8a",
      "line": 340,
      "relation": "increases",
      "source": 106,
      "subject": {
        "modifier": "Activity"
      },
      "target": 45
    },
    {
      "key": "7666e70cc506d9956dc14cae4ca625ae",
      "relation": "partOf",
      "source": 106,
      "target": 54
    },
    {
      "key": "cf30d5df61e5f7c7f175c6bdf16636b1",
      "relation": "partOf",
      "source": 106,
      "target": 79
    },
    {
      "key": "cf18e57ffaed145a2804a188f2a89e64",
      "relation": "partOf",
      "source": 106,
      "target": 69
    },
    {
      "key": "2fdffbc674c78e28bdc950cde8fd38c3",
      "relation": "partOf",
      "source": 106,
      "target": 61
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "For example, BAG-2 inhibits client ubiquitination by CHIP by interfering with the interaction between CHIP and E2 ubiquitin-conjugating enzymes [148].",
      "key": "5cd16b5be24cdf7a3bd6d110ace93a77",
      "line": 583,
      "relation": "increases",
      "source": 106,
      "subject": {
        "modifier": "Activity"
      },
      "target": 48
    },
    {
      "key": "7b10caa65c9c115f862b01ab08acf39a",
      "relation": "partOf",
      "source": 106,
      "target": 78
    },
    {
      "key": "671ed0c945254b84a0220d1c8e4cf973",
      "relation": "partOf",
      "source": 29,
      "target": 58
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "For example, the co-chaperones cdc37, a peptidyl-prolyl cis-trans isomerase (PPIase) family member, and p23 are all critical for the transfer of kinases to Hsp90 and maturation of the active protein [76,105]",
      "key": "46e2a8749f87069ea79c8e77440f97b6",
      "line": 347,
      "relation": "increases",
      "source": 104,
      "target": 58
    },
    {
      "key": "29c8d04c5368c2b216b4ebdc14ffb3c8",
      "relation": "partOf",
      "source": 104,
      "target": 68
    },
    {
      "key": "c959e74f90195af3e45d51e9ef961d56",
      "relation": "partOf",
      "source": 15,
      "target": 54
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "However, under potentially proteotoxic conditions, the post-translational modifications or mutations that damage tau’s affinity for microtubules and favor its aggregation are thought to generate a molecular ‘danger signal’ that specifically alerts the quality control system [112,113].",
      "key": "454c1273316139434ae05177a70705c9",
      "line": 369,
      "relation": "increases",
      "source": 100,
      "target": 22
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "However, under potentially proteotoxic conditions, the post-translational modifications or mutations that damage tau’s affinity for microtubules and favor its aggregation are thought to generate a molecular ‘danger signal’ that specifically alerts the quality control system [112,113].",
      "key": "f06300a53d3615b26b4985de936c7b3a",
      "line": 370,
      "relation": "decreases",
      "source": 100,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "However, under potentially proteotoxic conditions, the post-translational modifications or mutations that damage tau’s affinity for microtubules and favor its aggregation are thought to generate a molecular ‘danger signal’ that specifically alerts the quality control system [112,113].",
      "key": "1eef494b433b3e34b39afdb44c2a6af1",
      "line": 371,
      "relation": "association",
      "source": 100,
      "target": 47
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Hsp70 has been shown to both stabilize binding of tau to microtubules [114] and promote its degradation in combination with CHIP [115,116]",
      "key": "cbeaacde2bc8482d0e90f9cc2a209921",
      "line": 378,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 79,
      "target": 95
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "In addition, recent work has demonstrated that Hsc70, the constitutive cytosolic form of Hsp70s, also dynamically regulates the association of tau with microtubules",
      "key": "c0fee6007ebbdc1b01948ae5fd4176bc",
      "line": 384,
      "relation": "regulates",
      "source": 92,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "Low": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "In fact, recent work from our group has shown that inhibition of the ATPase activity of Hsp70/Hsc70 promotes proteasomal degradation of tau; whereas activation results in tau accumulation [117]",
      "key": "2fe2c1bce0363354b33d92903c82a0df",
      "line": 392,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "decreases",
      "source": 92,
      "subject": {
        "effect": {
          "name": "ATPase activity",
          "namespace": "GO"
        },
        "modifier": "Activity"
      },
      "target": 95
    },
    {
      "annotations": {
        "Confidence": {
          "Low": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "In fact, recent work from our group has shown that inhibition of the ATPase activity of Hsp70/Hsc70 promotes proteasomal degradation of tau; whereas activation results in tau accumulation [117]",
      "key": "ababdc2b0f5a8521426fafd43c5e5f08",
      "line": 394,
      "relation": "increases",
      "source": 92,
      "subject": {
        "modifier": "Activity"
      },
      "target": 95
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "However, this issue is more complicated, as other work has shown that chemical inhibition of Hsp90 by 17-AAG and other inhibitors reduces cellular levels of two phospho- tau species, pS202/T205 and pS396/S404, both of which are relevant to AD pathogenesis [119].",
      "key": "7667dd224ea10fde00a1d8c131ec8167",
      "line": 414,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 19,
      "target": 82
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "However, this issue is more complicated, as other work has shown that chemical inhibition of Hsp90 by 17-AAG and other inhibitors reduces cellular levels of two phospho- tau species, pS202/T205 and pS396/S404, both of which are relevant to AD pathogenesis [119].",
      "key": "fe74fb274de49753a74086a384f1ce1c",
      "line": 415,
      "relation": "decreases",
      "source": 19,
      "target": 98
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "However, this issue is more complicated, as other work has shown that chemical inhibition of Hsp90 by 17-AAG and other inhibitors reduces cellular levels of two phospho- tau species, pS202/T205 and pS396/S404, both of which are relevant to AD pathogenesis [119].",
      "key": "1b1f5244a2580ea929a4f672922e4189",
      "line": 416,
      "relation": "decreases",
      "source": 19,
      "target": 99
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "However, this issue is more complicated, as other work has shown that chemical inhibition of Hsp90 by 17-AAG and other inhibitors reduces cellular levels of two phospho- tau species, pS202/T205 and pS396/S404, both of which are relevant to AD pathogenesis [119].",
      "key": "09f67c90ba1d14c23dcadc636345afbe",
      "line": 417,
      "relation": "positiveCorrelation",
      "source": 98,
      "target": 115
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "However, this issue is more complicated, as other work has shown that chemical inhibition of Hsp90 by 17-AAG and other inhibitors reduces cellular levels of two phospho- tau species, pS202/T205 and pS396/S404, both of which are relevant to AD pathogenesis [119].",
      "key": "4125450395f96a1a9159f40a26138cd2",
      "line": 418,
      "relation": "positiveCorrelation",
      "source": 99,
      "target": 115
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "However, this issue is more complicated, as other work has shown that chemical inhibition of Hsp90 by 17-AAG and other inhibitors reduces cellular levels of two phospho- tau species, pS202/T205 and pS396/S404, both of which are relevant to AD pathogenesis [119].",
      "key": "a4b591b5ea03d9776365e3378d5f85f4",
      "line": 417,
      "relation": "positiveCorrelation",
      "source": 115,
      "target": 98
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "However, this issue is more complicated, as other work has shown that chemical inhibition of Hsp90 by 17-AAG and other inhibitors reduces cellular levels of two phospho- tau species, pS202/T205 and pS396/S404, both of which are relevant to AD pathogenesis [119].",
      "key": "eccbca82621d2da111c8ef60d9769555",
      "line": 418,
      "relation": "positiveCorrelation",
      "source": 115,
      "target": 99
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "BAG1 is upregulated in the hippocampus of AD patients [130], where it associates with tau and increases tau levels in cooperation with Hsp70 [131]",
      "key": "d1c8941e75564c341a9f69436adf31ad",
      "line": 470,
      "relation": "positiveCorrelation",
      "source": 115,
      "target": 85
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Interestingly, it was recently found that reducing the levels of Akt, another client of the Hsp90/CHIP complex, facilitates tau degradation [123], suggesting a synchronized balance between competing Hsp90 substrates that may be driven, in part, by their relative abundance or susceptibility to Hsp90 binding",
      "key": "3335e443730673b8ac087dadf5dc61f0",
      "line": 426,
      "relation": "association",
      "source": 84,
      "target": 69
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Interestingly, it was recently found that reducing the levels of Akt, another client of the Hsp90/CHIP complex, facilitates tau degradation [123], suggesting a synchronized balance between competing Hsp90 substrates that may be driven, in part, by their relative abundance or susceptibility to Hsp90 binding",
      "key": "ab7c76ca3af2aed801603c9b1d6057e5",
      "line": 427,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "negativeCorrelation",
      "source": 84,
      "target": 95
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Interestingly, it was recently found that reducing the levels of Akt, another client of the Hsp90/CHIP complex, facilitates tau degradation [123], suggesting a synchronized balance between competing Hsp90 substrates that may be driven, in part, by their relative abundance or susceptibility to Hsp90 binding",
      "key": "653ff96e4c748fb593e81bc194678e4f",
      "line": 426,
      "relation": "association",
      "source": 69,
      "target": 84
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Hsp27 has emerged as a potential target for tau regulation based on early findings that it preferentially binds to phosphorylated and hyperphosphorylated tau and promotes their clearance [125,126]",
      "key": "c176f75e35e962af3fa95816e1a7aa40",
      "line": 443,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 75,
      "target": 96
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Hsp27 has emerged as a potential target for tau regulation based on early findings that it preferentially binds to phosphorylated and hyperphosphorylated tau and promotes their clearance [125,126]",
      "key": "b7b43b482fbfcdeaf5ef016474b78ebb",
      "line": 442,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 76,
      "target": 97
    },
    {
      "key": "d55383f0322d35481c42b530bb4d0928",
      "relation": "partOf",
      "source": 28,
      "target": 57
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Recently, our group demonstrated that viral delivery of wild-type Hsp27 into the brains of tau-transgenic mice reduced tau levels and rescued long-term potentiation deficits.",
      "key": "f1a23ec44e9a605f66f0e97419522236",
      "line": 462,
      "relation": "positiveCorrelation",
      "source": 42,
      "target": 93
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "BAG1 is upregulated in the hippocampus of AD patients [130], where it associates with tau and increases tau levels in cooperation with Hsp70 [131]",
      "key": "8beb73e0cb0b6c2e7afd38aebcbb7ed8",
      "line": 470,
      "relation": "positiveCorrelation",
      "source": 85,
      "target": 115
    },
    {
      "key": "893b0a58ad213e66a8efdf56e6bb7b2b",
      "relation": "partOf",
      "source": 85,
      "target": 71
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "BAG1 is upregulated in the hippocampus of AD patients [130], where it associates with tau and increases tau levels in cooperation with Hsp70 [131]",
      "key": "b39a0fed4663ef43f36c40fa6e8be9c3",
      "line": 471,
      "relation": "directlyIncreases",
      "source": 85,
      "target": 71
    },
    {
      "key": "e90e180e605562a01c452f7b08a0429c",
      "relation": "partOf",
      "source": 85,
      "target": 72
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "BAG1 silencing decreases tau levels, consistent with a critical role for this co-chaperone in protecting tau from degradation.",
      "key": "18920f23478cc8f3317869377fc50f42",
      "line": 479,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "decreases",
      "source": 85,
      "target": 95
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "BAG1 is upregulated in the hippocampus of AD patients [130], where it associates with tau and increases tau levels in cooperation with Hsp70 [131]",
      "key": "a1da974928a7cf05c92e4bdde7818139",
      "line": 472,
      "relation": "increases",
      "source": 72,
      "target": 95
    },
    {
      "key": "c9194b86cba83fb1501be23946fe130c",
      "relation": "partOf",
      "source": 86,
      "target": 73
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "However, another related BAG family member, BAG2, interacts with Hsp70 and tau but, unlike BAG1, assists clearance of phosphorylated tau [132]",
      "key": "c1101784a203bda40344511c240fe947",
      "line": 485,
      "relation": "directlyIncreases",
      "source": 86,
      "target": 73
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "However, another related BAG family member, BAG2, interacts with Hsp70 and tau but, unlike BAG1, assists clearance of phosphorylated tau [132]",
      "key": "e44c10926bfc4da3d93ea11e2574c7eb",
      "line": 486,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "association",
      "source": 86,
      "target": 97
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "For example, BAG-2 inhibits client ubiquitination by CHIP by interfering with the interaction between CHIP and E2 ubiquitin-conjugating enzymes [148].",
      "key": "1941f94c0b14c0f9b81e33f4596a8d00",
      "line": 581,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 86,
      "target": 106
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "For example, BAG-2 inhibits client ubiquitination by CHIP by interfering with the interaction between CHIP and E2 ubiquitin-conjugating enzymes [148].",
      "key": "867000889bc5e33f498359e663e89c74",
      "line": 582,
      "relation": "decreases",
      "source": 86,
      "target": 48
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "For example, BAG-2 inhibits client ubiquitination by CHIP by interfering with the interaction between CHIP and E2 ubiquitin-conjugating enzymes [148].",
      "key": "83baffc6fbb4d1880eaaf992db6a5293",
      "line": 584,
      "relation": "decreases",
      "source": 86,
      "target": 78
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "This co-chaperone is of interest in tauopathies because Hsp110 knockout mice show an age-dependent accumulation of phosphorylated tau in the hippocampus [135].",
      "key": "2da87a414254f21d9193813a23df7b1e",
      "line": 495,
      "relation": "decreases",
      "source": 94,
      "target": 97
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Recently, the co-chaperone FK506-binding protein 51 kDa (FKBP51) has been implicated as a modulator of tau binding to microtubules",
      "key": "54f8c6bea23d220b7b8c5fb4e58eb147",
      "line": 503,
      "relation": "regulates",
      "source": 89,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "In relation to tau biology, FKBP51 enhances the association of Hsp90 with tau, co-localizes with tau in murine neurons, coimmunoprecipitates with tau in AD tissue samples and increases with age in an AD mouse model [136].",
      "key": "93a74b902124c911b4f5ce919220a0d5",
      "line": 510,
      "relation": "increases",
      "source": 89,
      "target": 67
    },
    {
      "key": "cad947ff9fd93f9b32c757b04226f17e",
      "relation": "partOf",
      "source": 89,
      "target": 74
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "In relation to tau biology, FKBP51 enhances the association of Hsp90 with tau, co-localizes with tau in murine neurons, coimmunoprecipitates with tau in AD tissue samples and increases with age in an AD mouse model [136].",
      "key": "6c15a3395d752e8a8545e33169f30d21",
      "line": 513,
      "relation": "directlyIncreases",
      "source": 89,
      "target": 74
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "In relation to tau biology, FKBP51 enhances the association of Hsp90 with tau, co-localizes with tau in murine neurons, coimmunoprecipitates with tau in AD tissue samples and increases with age in an AD mouse model [136].",
      "key": "d106582c58468e046251961b53245fab",
      "line": 514,
      "relation": "positiveCorrelation",
      "source": 89,
      "target": 49
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "These interactions may be functionally important because silencing FKBP51 reduces tau and phosphorylated-tau levels [136].",
      "key": "d65c95cafc54528be656fd5e8bfabdbc",
      "line": 522,
      "relation": "increases",
      "source": 89,
      "target": 95
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "These interactions may be functionally important because silencing FKBP51 reduces tau and phosphorylated-tau levels [136].",
      "key": "ab8858c4e06a643c371c7d94e859aace",
      "line": 523,
      "relation": "increases",
      "source": 89,
      "target": 97
    },
    {
      "key": "3ed0a06e99caa96a4f62b63efb62f32b",
      "relation": "partOf",
      "source": 89,
      "target": 66
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Finally, the FKBP51–Hsp90 complex has been proposed to be responsible for the interaction of tau with phosphatases, helping to restore binding to microtubules [137].",
      "key": "b5856a6377c195c3b950183e9eb9195f",
      "line": 529,
      "relation": "increases",
      "source": 66,
      "target": 59
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "This model is consistent with the data that hyperphosphorylated tau appears to be specifically selected for degradation by some chaperone machines, such as the Hsp90–FKBP51 complex, without effects on normal tau [132,136].",
      "key": "df3988e7595de5f60477200a6e97b90a",
      "line": 566,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 66,
      "target": 96
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "This model is consistent with the data that hyperphosphorylated tau appears to be specifically selected for degradation by some chaperone machines, such as the Hsp90–FKBP51 complex, without effects on normal tau [132,136].",
      "key": "b23434129a6e70387f1e137e856bd4a3",
      "line": 567,
      "relation": "causesNoChange",
      "source": 66,
      "target": 95
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Finally, the FKBP51–Hsp90 complex has been proposed to be responsible for the interaction of tau with phosphatases, helping to restore binding to microtubules [137].",
      "key": "07d6678e1d88693c274f79923374cce1",
      "line": 530,
      "relation": "increases",
      "source": 59,
      "target": 56
    },
    {
      "key": "2f4a43127612caac5299f2dd5ca77cfa",
      "relation": "partOf",
      "source": 30,
      "target": 59
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "In this model,accumulation of an Hsp70–substrate complex (either via treatment with chemical inhibitors or because of intrinsic properties of the substrate) might allow enough time for a degradation factor (e.g., CHIP) to bind and facilitate polyubiquitination.",
      "key": "1195a1d833c931dcb640234bfbf365f6",
      "line": 537,
      "relation": "positiveCorrelation",
      "source": 62,
      "target": 61
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "In this model,accumulation of an Hsp70–substrate complex (either via treatment with chemical inhibitors or because of intrinsic properties of the substrate) might allow enough time for a degradation factor (e.g., CHIP) to bind and facilitate polyubiquitination.",
      "key": "d5f9aab03e3f91d575ff3c3df4af8f5e",
      "line": 537,
      "relation": "positiveCorrelation",
      "source": 61,
      "target": 62
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "In this model,accumulation of an Hsp70–substrate complex (either via treatment with chemical inhibitors or because of intrinsic properties of the substrate) might allow enough time for a degradation factor (e.g., CHIP) to bind and facilitate polyubiquitination.",
      "key": "9b7f29d9ac408959ec4af06f43348824",
      "line": 538,
      "relation": "increases",
      "source": 61,
      "target": 46
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "For example, Hsp90 inhibitors cause degradation of tau and many cancer-related substrates [85].",
      "key": "5ccc2ff8d0d799971f22e5f8f7ba43e1",
      "line": 544,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 0,
      "target": 95
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Moreover, these compounds were found to prolong binding of Hsp90 to a model substrate, which was sufficient to promote its degradation [142]",
      "key": "1807fbf319b83fa6fbe7098b0b830128",
      "line": 551,
      "relation": "increases",
      "source": 0,
      "target": 60
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "Moreover, these compounds were found to prolong binding of Hsp90 to a model substrate, which was sufficient to promote its degradation [142]",
      "key": "dc82c284032cf5380fe50fa7219cf55f",
      "line": 552,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 60,
      "target": 31
    },
    {
      "key": "364b5922128e271ba3afe598edbc4b01",
      "relation": "partOf",
      "source": 107,
      "target": 78
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "In another example, McClellan et al. showed that von Hippel–Lindau tumor-suppressor protein requires Hsp70 for its folding and degradation, whereas Hsp90 is only required for degradation [149].",
      "key": "40094ba1f3a2c553562b120c7edef189",
      "line": 591,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 80,
      "target": 108
    },
    {
      "key": "ce7002c2bf1d2aee38d3c6bc61b3c481",
      "relation": "partOf",
      "source": 108,
      "target": 80
    },
    {
      "key": "284b0c1935f6286dde057740607cdf9b",
      "relation": "partOf",
      "source": 108,
      "target": 70
    },
    {
      "key": "daa4fd3996f64869f5863b6c6618ad44",
      "relation": "partOf",
      "source": 108,
      "target": 77
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "In another example, McClellan et al. showed that von Hippel–Lindau tumor-suppressor protein requires Hsp70 for its folding and degradation, whereas Hsp90 is only required for degradation [149].",
      "key": "59a578547c40bd1b7f0127a952fe90f9",
      "line": 592,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 70,
      "target": 108
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Dickey CA",
          "Gestwicki JE",
          "Kiray J",
          "Koren J",
          "Miyata Y"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21882945",
        "db_name": "Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.",
        "first": "Miyata Y",
        "journal": "Future medicinal chemistry",
        "last": "Gestwicki JE",
        "pages": "1523-37",
        "volume": "3"
      },
      "evidence": "HOP was also required for degradation, indicating that transfer of von Hippel–Lindau from the Hsp70 complex to Hsp90 is a necessary part of its degradation pathway.",
      "key": "5504678fc9296e66f71023dab2142dbd",
      "line": 600,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 77,
      "target": 108
    },
    {
      "key": "e698578e4db3ae81f849d2a31d19f8d0",
      "relation": "partOf",
      "source": 105,
      "target": 77
    }
  ],
  "multigraph": true,
  "nodes": [
    {
      "bel": "a(CHEBI:\"Hsp90 inhibitor\")",
      "concept": {
        "name": "Hsp90 inhibitor",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "14fcefb3a82be1a7d77909d598c08735"
    },
    {
      "bel": "a(CHEBI:\"NMDA receptor antagonist\")",
      "concept": {
        "name": "NMDA receptor antagonist",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "98259a7a4485d8deb63c87637c5bed63"
    },
    {
      "bel": "a(CHEBI:\"amyloid-beta\")",
      "concept": {
        "name": "amyloid-beta",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "e9557ea6ec74113b73fe23f4bd76b524"
    },
    {
      "bel": "a(CHEBI:\"methylene blue\")",
      "concept": {
        "name": "methylene blue",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "7beb4cf796511846dabed14b6118ee48"
    },
    {
      "bel": "a(CHEBI:\"phosphate(3-)\")",
      "concept": {
        "name": "phosphate(3-)",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "fb6fd08200f6469cca623b134c5ac56f"
    },
    {
      "bel": "a(CHEBI:ADP)",
      "concept": {
        "name": "ADP",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "1fd3a946ceefb4e6928ddd6a81a814b1"
    },
    {
      "bel": "a(CHEBI:ATP)",
      "concept": {
        "name": "ATP",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "08c2bd47cf55782389bbaba34887a39c"
    },
    {
      "bel": "a(CHEBI:adenosine)",
      "concept": {
        "name": "adenosine",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "47a9115e40f8bcf8b2b8deb3faa4231b"
    },
    {
      "bel": "a(CHEBI:anthraquinone)",
      "concept": {
        "name": "anthraquinone",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "01685999d3d842acfb8fdd88d76c810d"
    },
    {
      "bel": "a(CHEBI:benzothiazoles)",
      "concept": {
        "name": "benzothiazoles",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "d1a507b096bd76d5d1f7240379e432fc"
    },
    {
      "bel": "a(CHEBI:celastrol)",
      "concept": {
        "name": "celastrol",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "46babe7e575feed897c39450b09af429"
    },
    {
      "bel": "a(CHEBI:geldanamycin)",
      "concept": {
        "name": "geldanamycin",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "4767be33706df692ba80c3ee3f800321"
    },
    {
      "bel": "a(CHEBI:novobiocin)",
      "concept": {
        "name": "novobiocin",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "57a8a71df3a89ec463992810a82c96df"
    },
    {
      "bel": "a(CHEBI:phenothiazines)",
      "concept": {
        "name": "phenothiazines",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "01a5c176d09d17394ecbd5513578672a"
    },
    {
      "bel": "a(CHEBI:polyamine)",
      "concept": {
        "name": "polyamine",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "8dc50a50c849a20982619e664bb4669c"
    },
    {
      "bel": "a(CHEBI:polypeptide)",
      "concept": {
        "name": "polypeptide",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "47e208b9c8388ce3fe475252a0720dca"
    },
    {
      "bel": "a(CHEBI:polyphenol)",
      "concept": {
        "name": "polyphenol",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "fdfacabcdaa49ee91452cbdae35ed2c4"
    },
    {
      "bel": "a(CHEBI:radicicol)",
      "concept": {
        "name": "radicicol",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "85054d7cf074e9f1d70521d45ff38b32"
    },
    {
      "bel": "a(CHEBI:rhodanine)",
      "concept": {
        "name": "rhodanine",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "d000af83acc970fbf7e53745921ab16f"
    },
    {
      "bel": "a(CHEBI:tanespimycin)",
      "concept": {
        "name": "tanespimycin",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "b6850241cac2c4aa77190fa5db86fc60"
    },
    {
      "bel": "a(CONSO:\"Hsp27 oligomers\")",
      "concept": {
        "name": "Hsp27 oligomers",
        "namespace": "CONSO"
      },
      "function": "Abundance",
      "id": "75043a8f9c77450dce7b67f9be80e7ac"
    },
    {
      "bel": "a(CONSO:\"Phenylthiazolyl-hydrazide\")",
      "concept": {
        "name": "Phenylthiazolyl-hydrazide",
        "namespace": "CONSO"
      },
      "function": "Abundance",
      "id": "70a4f4f27c3c20e74fdde2de3372c028"
    },
    {
      "bel": "a(CONSO:\"Tau aggregates\")",
      "concept": {
        "name": "Tau aggregates",
        "namespace": "CONSO"
      },
      "function": "Abundance",
      "id": "8e1da50e6008ffdd1b37825776666311"
    },
    {
      "bel": "a(GO:microtubule)",
      "concept": {
        "name": "microtubule",
        "namespace": "GO"
      },
      "function": "Abundance",
      "id": "0fe6be9622e5650da7dca7cdced2f9db"
    },
    {
      "bel": "a(MESH:\"Adenosine Triphosphatases\")",
      "concept": {
        "name": "Adenosine Triphosphatases",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "c192675bd650d27466259012b3f90346"
    },
    {
      "bel": "a(MESH:\"Guanine Nucleotide Exchange Factors\")",
      "concept": {
        "name": "Guanine Nucleotide Exchange Factors",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "e474c1b8a021df4068a5ebd15e0cd7c0"
    },
    {
      "bel": "a(MESH:\"Heat-Shock Proteins\")",
      "concept": {
        "name": "Heat-Shock Proteins",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "6181ded5b8ed84637921ec420d06c405"
    },
    {
      "bel": "a(MESH:\"Molecular Chaperones\")",
      "concept": {
        "name": "Molecular Chaperones",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "915181828da37044d70691bae6ff6176"
    },
    {
      "bel": "a(MESH:\"Neurofibrillary Tangles\")",
      "concept": {
        "name": "Neurofibrillary Tangles",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "1ea09b7aace0ed3a0da3f815bd92b304"
    },
    {
      "bel": "a(MESH:\"Protein Kinases\")",
      "concept": {
        "name": "Protein Kinases",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "4aeb40be82456e672b2c66f404e48b87"
    },
    {
      "bel": "a(MESH:\"Protein Phosphatase 2\")",
      "concept": {
        "name": "Protein Phosphatase 2",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "892c61d52f68eeaa16241cb9e712f86f"
    },
    {
      "bel": "a(MESH:Proteins)",
      "concept": {
        "name": "Proteins",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "d5c3043be47366598a45199bf0e779a8"
    },
    {
      "bel": "a(PUBCHEM:1056)",
      "concept": {
        "name": "1056",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "73a35d615c4046a9391dacc7244c906a"
    },
    {
      "bel": "a(PUBCHEM:134222899)",
      "concept": {
        "name": "134222899",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "50cc4913ab7bfb8da6254e5ce31ae3bb"
    },
    {
      "bel": "a(PUBCHEM:25195348)",
      "concept": {
        "name": "25195348",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "8494fed560ab6b59721ce4101f9fbd84"
    },
    {
      "bel": "a(PUBCHEM:501026)",
      "concept": {
        "name": "501026",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "d7c6c5632f1107a93335a878271829ab"
    },
    {
      "bel": "a(PUBCHEM:53789478)",
      "concept": {
        "name": "53789478",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "d94d729201f0fbbabec6635350e68222"
    },
    {
      "bel": "a(PUBCHEM:6444403)",
      "concept": {
        "name": "6444403",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "46078be3cc583e9726249dd965087718"
    },
    {
      "bel": "a(PUBCHEM:6505803)",
      "concept": {
        "name": "6505803",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "f7dc15a819f82103bc832c18d188be25"
    },
    {
      "bel": "a(PUBCHEM:9549213)",
      "concept": {
        "name": "9549213",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "6aaf2eb96c5add0b4d71e6f9cb164454"
    },
    {
      "bel": "bp(CONSO:Proteostasis)",
      "concept": {
        "name": "Proteostasis",
        "namespace": "CONSO"
      },
      "function": "BiologicalProcess",
      "id": "6956667aa69f38988f14d8d983ea7f8e"
    },
    {
      "bel": "bp(GO:\"cellular response to stress\")",
      "concept": {
        "name": "cellular response to stress",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "4b4228e207b3004b2cf3c07896ae1c8a"
    },
    {
      "bel": "bp(GO:\"long-term synaptic potentiation\")",
      "concept": {
        "name": "long-term synaptic potentiation",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "ab5cdc5c0ef7a3c4b3461ab4dcfa6730"
    },
    {
      "bel": "bp(GO:\"neuron death\")",
      "concept": {
        "name": "neuron death",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "5af039c1f3120f7215931236c3c03804"
    },
    {
      "bel": "bp(GO:\"proteasomal protein catabolic process\")",
      "concept": {
        "name": "proteasomal protein catabolic process",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "93e714476cce4befb498395cb274811e"
    },
    {
      "bel": "bp(GO:\"protein catabolic process\")",
      "concept": {
        "name": "protein catabolic process",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "b670adb6c51d1078c8508e861db111a1"
    },
    {
      "bel": "bp(GO:\"protein polyubiquitination\")",
      "concept": {
        "name": "protein polyubiquitination",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "44a79704f830efae3dc7dfd89459d6c4"
    },
    {
      "bel": "bp(GO:\"protein quality control for misfolded or incompletely synthesized proteins\")",
      "concept": {
        "name": "protein quality control for misfolded or incompletely synthesized proteins",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "01e3d459cfff05d3b9f75abd89a1e16c"
    },
    {
      "bel": "bp(GO:\"protein ubiquitination\")",
      "concept": {
        "name": "protein ubiquitination",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "d8ca377fd2729397efd3be0187b6e326"
    },
    {
      "bel": "bp(GO:aging)",
      "concept": {
        "name": "aging",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "77570756b71db14efd4d1aefc49bec11"
    },
    {
      "bel": "bp(GO:autophagy)",
      "concept": {
        "name": "autophagy",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "9efc965fac6a195d0fad26eecddaac05"
    },
    {
      "bel": "bp(GO:cognition)",
      "concept": {
        "name": "cognition",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "24220ec2073c35bcd945681ee9c6ea38"
    },
    {
      "bel": "bp(GO:phosphorylation)",
      "concept": {
        "name": "phosphorylation",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "ddd7ac3c981b2d3dc4cce6c1e7837bb9"
    },
    {
      "bel": "complex(a(CHEBI:novobiocin), p(INTERPRO:\"HSP90, C-terminal domain\"))",
      "function": "Complex",
      "id": "461ebba8a1a8f80c9ff11bbd08d84186",
      "members": [
        {
          "bel": "a(CHEBI:novobiocin)",
          "concept": {
            "name": "novobiocin",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "57a8a71df3a89ec463992810a82c96df"
        },
        {
          "bel": "p(INTERPRO:\"HSP90, C-terminal domain\")",
          "concept": {
            "name": "HSP90, C-terminal domain",
            "namespace": "INTERPRO"
          },
          "function": "Protein",
          "id": "8a3e87a637932f989fd2e3abc8297716"
        }
      ]
    },
    {
      "bel": "complex(a(CHEBI:polypeptide), p(HGNC:STUB1))",
      "function": "Complex",
      "id": "6f2c32ef55ac3c8ed725fc2bb9bf8d5f",
      "members": [
        {
          "bel": "a(CHEBI:polypeptide)",
          "concept": {
            "name": "polypeptide",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "47e208b9c8388ce3fe475252a0720dca"
        },
        {
          "bel": "p(HGNC:STUB1)",
          "concept": {
            "name": "STUB1",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "d87d73cafef28fc2c05ea70f059c61a4"
        }
      ]
    },
    {
      "bel": "complex(a(CHEBI:radicicol), p(INTERPRO:\"Heat shock protein Hsp90, N-terminal\"))",
      "function": "Complex",
      "id": "f670d20d0ce5376338f938ee791c47ca",
      "members": [
        {
          "bel": "a(CHEBI:radicicol)",
          "concept": {
            "name": "radicicol",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "85054d7cf074e9f1d70521d45ff38b32"
        },
        {
          "bel": "p(INTERPRO:\"Heat shock protein Hsp90, N-terminal\")",
          "concept": {
            "name": "Heat shock protein Hsp90, N-terminal",
            "namespace": "INTERPRO"
          },
          "function": "Protein",
          "id": "404ded91bc7dea3351f3a1d020bb4ad2"
        }
      ]
    },
    {
      "bel": "complex(a(GO:microtubule), p(HGNC:MAPT))",
      "function": "Complex",
      "id": "60e49c33ee1c6bbff236bae4989f16eb",
      "members": [
        {
          "bel": "a(GO:microtubule)",
          "concept": {
            "name": "microtubule",
            "namespace": "GO"
          },
          "function": "Abundance",
          "id": "0fe6be9622e5650da7dca7cdced2f9db"
        },
        {
          "bel": "p(HGNC:MAPT)",
          "concept": {
            "name": "MAPT",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "7d1009217050e75d549c8c5aa83309a8"
        }
      ]
    },
    {
      "bel": "complex(a(MESH:\"Neurofibrillary Tangles\"), p(HGNC:HSPB1))",
      "function": "Complex",
      "id": "a1c92452d6d6bcbca836e293fb0c7ea9",
      "members": [
        {
          "bel": "a(MESH:\"Neurofibrillary Tangles\")",
          "concept": {
            "name": "Neurofibrillary Tangles",
            "namespace": "MESH"
          },
          "function": "Abundance",
          "id": "1ea09b7aace0ed3a0da3f815bd92b304"
        },
        {
          "bel": "p(HGNC:HSPB1)",
          "concept": {
            "name": "HSPB1",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "d5b5de04c466b9b3d8edde293c1f2a4f"
        }
      ]
    },
    {
      "bel": "complex(a(MESH:\"Protein Kinases\"), p(FPLX:HSP90))",
      "function": "Complex",
      "id": "355afcff9178ccabec5c17327d18d68e",
      "members": [
        {
          "bel": "a(MESH:\"Protein Kinases\")",
          "concept": {
            "name": "Protein Kinases",
            "namespace": "MESH"
          },
          "function": "Abundance",
          "id": "4aeb40be82456e672b2c66f404e48b87"
        },
        {
          "bel": "p(FPLX:HSP90)",
          "concept": {
            "name": "HSP90",
            "namespace": "FPLX"
          },
          "function": "Protein",
          "id": "1d25d355c41148f8c1322364b79179e4"
        }
      ]
    },
    {
      "bel": "complex(a(MESH:\"Protein Phosphatase 2\"), p(HGNC:MAPT))",
      "function": "Complex",
      "id": "a326bd6f1f576cf89bca8a72d9f9ccff",
      "members": [
        {
          "bel": "a(MESH:\"Protein Phosphatase 2\")",
          "concept": {
            "name": "Protein Phosphatase 2",
            "namespace": "MESH"
          },
          "function": "Abundance",
          "id": "892c61d52f68eeaa16241cb9e712f86f"
        },
        {
          "bel": "p(HGNC:MAPT)",
          "concept": {
            "name": "MAPT",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "7d1009217050e75d549c8c5aa83309a8"
        }
      ]
    },
    {
      "bel": "complex(a(MESH:Proteins), p(FPLX:HSP90))",
      "function": "Complex",
      "id": "f96f85e6eb019ff40fff4a457a70a5c0",
      "members": [
        {
          "bel": "a(MESH:Proteins)",
          "concept": {
            "name": "Proteins",
            "namespace": "MESH"
          },
          "function": "Abundance",
          "id": "d5c3043be47366598a45199bf0e779a8"
        },
        {
          "bel": "p(FPLX:HSP90)",
          "concept": {
            "name": "HSP90",
            "namespace": "FPLX"
          },
          "function": "Protein",
          "id": "1d25d355c41148f8c1322364b79179e4"
        }
      ]
    },
    {
      "bel": "complex(a(MESH:Proteins), p(HGNC:STUB1), p(INTERPRO:\"Heat shock protein 70 family\"))",
      "function": "Complex",
      "id": "690b085d791e4581a110ba77220333e4",
      "members": [
        {
          "bel": "a(MESH:Proteins)",
          "concept": {
            "name": "Proteins",
            "namespace": "MESH"
          },
          "function": "Abundance",
          "id": "d5c3043be47366598a45199bf0e779a8"
        },
        {
          "bel": "p(HGNC:STUB1)",
          "concept": {
            "name": "STUB1",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "d87d73cafef28fc2c05ea70f059c61a4"
        },
        {
          "bel": "p(INTERPRO:\"Heat shock protein 70 family\")",
          "concept": {
            "name": "Heat shock protein 70 family",
            "namespace": "INTERPRO"
          },
          "function": "Protein",
          "id": "43387e6260ac862bb69d16380eb79e5f"
        }
      ]
    },
    {
      "bel": "complex(a(MESH:Proteins), p(INTERPRO:\"Heat shock protein 70 family\"))",
      "function": "Complex",
      "id": "ab43808629fa812614395a1eaa9234a7",
      "members": [
        {
          "bel": "a(MESH:Proteins)",
          "concept": {
            "name": "Proteins",
            "namespace": "MESH"
          },
          "function": "Abundance",
          "id": "d5c3043be47366598a45199bf0e779a8"
        },
        {
          "bel": "p(INTERPRO:\"Heat shock protein 70 family\")",
          "concept": {
            "name": "Heat shock protein 70 family",
            "namespace": "INTERPRO"
          },
          "function": "Protein",
          "id": "43387e6260ac862bb69d16380eb79e5f"
        }
      ]
    },
    {
      "bel": "complex(a(PUBCHEM:501026), p(INTERPRO:\"HSP90, C-terminal domain\"))",
      "function": "Complex",
      "id": "0b3c0de85d82708e132653df8722cb14",
      "members": [
        {
          "bel": "a(PUBCHEM:501026)",
          "concept": {
            "name": "501026",
            "namespace": "PUBCHEM"
          },
          "function": "Abundance",
          "id": "d7c6c5632f1107a93335a878271829ab"
        },
        {
          "bel": "p(INTERPRO:\"HSP90, C-terminal domain\")",
          "concept": {
            "name": "HSP90, C-terminal domain",
            "namespace": "INTERPRO"
          },
          "function": "Protein",
          "id": "8a3e87a637932f989fd2e3abc8297716"
        }
      ]
    },
    {
      "bel": "complex(a(PUBCHEM:9549213), p(INTERPRO:\"Heat shock protein Hsp90, N-terminal\"))",
      "function": "Complex",
      "id": "8de2b86205b0a7bb4b35a6c643bbade5",
      "members": [
        {
          "bel": "a(PUBCHEM:9549213)",
          "concept": {
            "name": "9549213",
            "namespace": "PUBCHEM"
          },
          "function": "Abundance",
          "id": "6aaf2eb96c5add0b4d71e6f9cb164454"
        },
        {
          "bel": "p(INTERPRO:\"Heat shock protein Hsp90, N-terminal\")",
          "concept": {
            "name": "Heat shock protein Hsp90, N-terminal",
            "namespace": "INTERPRO"
          },
          "function": "Protein",
          "id": "404ded91bc7dea3351f3a1d020bb4ad2"
        }
      ]
    },
    {
      "bel": "complex(p(FPLX:HSP90), p(FPLX:HSP90))",
      "function": "Complex",
      "id": "1a99fcefd484157caab7f548e5d05794",
      "members": [
        {
          "bel": "p(FPLX:HSP90)",
          "concept": {
            "name": "HSP90",
            "namespace": "FPLX"
          },
          "function": "Protein",
          "id": "1d25d355c41148f8c1322364b79179e4"
        },
        {
          "bel": "p(FPLX:HSP90)",
          "concept": {
            "name": "HSP90",
            "namespace": "FPLX"
          },
          "function": "Protein",
          "id": "1d25d355c41148f8c1322364b79179e4"
        }
      ]
    },
    {
      "bel": "complex(p(FPLX:HSP90), p(HGNC:FKBP5))",
      "function": "Complex",
      "id": "459764d5552b26c9df6b4ad303b00deb",
      "members": [
        {
          "bel": "p(FPLX:HSP90)",
          "concept": {
            "name": "HSP90",
            "namespace": "FPLX"
          },
          "function": "Protein",
          "id": "1d25d355c41148f8c1322364b79179e4"
        },
        {
          "bel": "p(HGNC:FKBP5)",
          "concept": {
            "name": "FKBP5",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "6cdfe5e08dbab001c43d1af3146cfb92"
        }
      ]
    },
    {
      "bel": "complex(p(FPLX:HSP90), p(HGNC:MAPT))",
      "function": "Complex",
      "id": "469b6c48d6b53ed924318d600dce44b2",
      "members": [
        {
          "bel": "p(FPLX:HSP90)",
          "concept": {
            "name": "HSP90",
            "namespace": "FPLX"
          },
          "function": "Protein",
          "id": "1d25d355c41148f8c1322364b79179e4"
        },
        {
          "bel": "p(HGNC:MAPT)",
          "concept": {
            "name": "MAPT",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "7d1009217050e75d549c8c5aa83309a8"
        }
      ]
    },
    {
      "bel": "complex(p(FPLX:HSP90), p(HGNC:PTGES3))",
      "function": "Complex",
      "id": "e98e059693d6d2075c5855bce23745c5",
      "members": [
        {
          "bel": "p(FPLX:HSP90)",
          "concept": {
            "name": "HSP90",
            "namespace": "FPLX"
          },
          "function": "Protein",
          "id": "1d25d355c41148f8c1322364b79179e4"
        },
        {
          "bel": "p(HGNC:PTGES3)",
          "concept": {
            "name": "PTGES3",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "f3cf891b5455730db56f755ea78283ad"
        }
      ]
    },
    {
      "bel": "complex(p(FPLX:HSP90), p(HGNC:STUB1))",
      "function": "Complex",
      "id": "1fb3f851a506bb5a3778582e81a17b8e",
      "members": [
        {
          "bel": "p(FPLX:HSP90)",
          "concept": {
            "name": "HSP90",
            "namespace": "FPLX"
          },
          "function": "Protein",
          "id": "1d25d355c41148f8c1322364b79179e4"
        },
        {
          "bel": "p(HGNC:STUB1)",
          "concept": {
            "name": "STUB1",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "d87d73cafef28fc2c05ea70f059c61a4"
        }
      ]
    },
    {
      "bel": "complex(p(FPLX:HSP90), p(HGNC:VHL))",
      "function": "Complex",
      "id": "878d476cc156767bc668fcfb93833112",
      "members": [
        {
          "bel": "p(FPLX:HSP90)",
          "concept": {
            "name": "HSP90",
            "namespace": "FPLX"
          },
          "function": "Protein",
          "id": "1d25d355c41148f8c1322364b79179e4"
        },
        {
          "bel": "p(HGNC:VHL)",
          "concept": {
            "name": "VHL",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "51ee7ec3981d10efa166f95b9b4fc8d0"
        }
      ]
    },
    {
      "bel": "complex(p(HGNC:BAG1), p(HGNC:MAPT))",
      "function": "Complex",
      "id": "ea7ee99328a0df1ebd9ca9e9a20d8809",
      "members": [
        {
          "bel": "p(HGNC:BAG1)",
          "concept": {
            "name": "BAG1",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "e99a022dd6d96a105b9a599748e7cf66"
        },
        {
          "bel": "p(HGNC:MAPT)",
          "concept": {
            "name": "MAPT",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "7d1009217050e75d549c8c5aa83309a8"
        }
      ]
    },
    {
      "bel": "complex(p(HGNC:BAG1), p(INTERPRO:\"Heat shock protein 70 family\"))",
      "function": "Complex",
      "id": "3d4d75a321faaae0015bad99ec9e79c4",
      "members": [
        {
          "bel": "p(HGNC:BAG1)",
          "concept": {
            "name": "BAG1",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "e99a022dd6d96a105b9a599748e7cf66"
        },
        {
          "bel": "p(INTERPRO:\"Heat shock protein 70 family\")",
          "concept": {
            "name": "Heat shock protein 70 family",
            "namespace": "INTERPRO"
          },
          "function": "Protein",
          "id": "43387e6260ac862bb69d16380eb79e5f"
        }
      ]
    },
    {
      "bel": "complex(p(HGNC:BAG2), p(HGNC:MAPT), p(INTERPRO:\"Heat shock protein 70 family\"))",
      "function": "Complex",
      "id": "a7754909c9180bce2d57d3b152c7c91e",
      "members": [
        {
          "bel": "p(HGNC:BAG2)",
          "concept": {
            "name": "BAG2",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "1aa87e6eae4239d02cccdb3f23b02548"
        },
        {
          "bel": "p(HGNC:MAPT)",
          "concept": {
            "name": "MAPT",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "7d1009217050e75d549c8c5aa83309a8"
        },
        {
          "bel": "p(INTERPRO:\"Heat shock protein 70 family\")",
          "concept": {
            "name": "Heat shock protein 70 family",
            "namespace": "INTERPRO"
          },
          "function": "Protein",
          "id": "43387e6260ac862bb69d16380eb79e5f"
        }
      ]
    },
    {
      "bel": "complex(p(HGNC:FKBP5), p(HGNC:MAPT))",
      "function": "Complex",
      "id": "a629997837e7ab370b6235844b61806c",
      "members": [
        {
          "bel": "p(HGNC:FKBP5)",
          "concept": {
            "name": "FKBP5",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "6cdfe5e08dbab001c43d1af3146cfb92"
        },
        {
          "bel": "p(HGNC:MAPT)",
          "concept": {
            "name": "MAPT",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "7d1009217050e75d549c8c5aa83309a8"
        }
      ]
    },
    {
      "bel": "complex(p(HGNC:HSPB1), p(HGNC:MAPT, pmod(CONSO:hyperphosphorylation)))",
      "function": "Complex",
      "id": "b7611f29f2df365f8fb1c0bf429382af",
      "members": [
        {
          "bel": "p(HGNC:HSPB1)",
          "concept": {
            "name": "HSPB1",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "d5b5de04c466b9b3d8edde293c1f2a4f"
        },
        {
          "bel": "p(HGNC:MAPT, pmod(CONSO:hyperphosphorylation))",
          "concept": {
            "name": "MAPT",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "0d2d8072f03dcdf148e658067d37b9cb",
          "variants": [
            {
              "concept": {
                "name": "hyperphosphorylation",
                "namespace": "CONSO"
              },
              "kind": "pmod"
            }
          ]
        }
      ]
    },
    {
      "bel": "complex(p(HGNC:HSPB1), p(HGNC:MAPT, pmod(Ph)))",
      "function": "Complex",
      "id": "f3869b701442af9285dfbcb85863afea",
      "members": [
        {
          "bel": "p(HGNC:HSPB1)",
          "concept": {
            "name": "HSPB1",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "d5b5de04c466b9b3d8edde293c1f2a4f"
        },
        {
          "bel": "p(HGNC:MAPT, pmod(Ph))",
          "concept": {
            "name": "MAPT",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "a8fb3a87d5a0672c07462bb17c8b0947",
          "variants": [
            {
              "concept": {
                "name": "Ph",
                "namespace": "bel"
              },
              "kind": "pmod"
            }
          ]
        }
      ]
    },
    {
      "bel": "complex(p(HGNC:STIP1), p(HGNC:VHL))",
      "function": "Complex",
      "id": "7dd2fdeaa6be830a540f67ecc616eb2f",
      "members": [
        {
          "bel": "p(HGNC:STIP1)",
          "concept": {
            "name": "STIP1",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "1afa5f431569f21a745c9ac99d1386a3"
        },
        {
          "bel": "p(HGNC:VHL)",
          "concept": {
            "name": "VHL",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "51ee7ec3981d10efa166f95b9b4fc8d0"
        }
      ]
    },
    {
      "bel": "complex(p(HGNC:STUB1), p(HGNC:UBA2))",
      "function": "Complex",
      "id": "92d7ea683975ecb2ad25730da19232cd",
      "members": [
        {
          "bel": "p(HGNC:STUB1)",
          "concept": {
            "name": "STUB1",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "d87d73cafef28fc2c05ea70f059c61a4"
        },
        {
          "bel": "p(HGNC:UBA2)",
          "concept": {
            "name": "UBA2",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "323fc386413cd10537097b7a2853e366"
        }
      ]
    },
    {
      "bel": "complex(p(HGNC:STUB1), p(INTERPRO:\"Heat shock protein 70 family\"))",
      "function": "Complex",
      "id": "24dd88b0020aa9dd63a66075bcb25575",
      "members": [
        {
          "bel": "p(HGNC:STUB1)",
          "concept": {
            "name": "STUB1",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "d87d73cafef28fc2c05ea70f059c61a4"
        },
        {
          "bel": "p(INTERPRO:\"Heat shock protein 70 family\")",
          "concept": {
            "name": "Heat shock protein 70 family",
            "namespace": "INTERPRO"
          },
          "function": "Protein",
          "id": "43387e6260ac862bb69d16380eb79e5f"
        }
      ]
    },
    {
      "bel": "complex(p(HGNC:VHL), p(INTERPRO:\"Heat shock protein 70 family\"))",
      "function": "Complex",
      "id": "7899f19292e06a9b202d91e1aaacb61f",
      "members": [
        {
          "bel": "p(HGNC:VHL)",
          "concept": {
            "name": "VHL",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "51ee7ec3981d10efa166f95b9b4fc8d0"
        },
        {
          "bel": "p(INTERPRO:\"Heat shock protein 70 family\")",
          "concept": {
            "name": "Heat shock protein 70 family",
            "namespace": "INTERPRO"
          },
          "function": "Protein",
          "id": "43387e6260ac862bb69d16380eb79e5f"
        }
      ]
    },
    {
      "bel": "complex(p(INTERPRO:\"Chaperone J-domain superfamily\"), p(INTERPRO:\"Heat shock protein 70 family\"))",
      "function": "Complex",
      "id": "2dbca3b20e5c3d300960c074bb016b90",
      "members": [
        {
          "bel": "p(INTERPRO:\"Chaperone J-domain superfamily\")",
          "concept": {
            "name": "Chaperone J-domain superfamily",
            "namespace": "INTERPRO"
          },
          "function": "Protein",
          "id": "0b3db1de5a21d5d78cf0a952eb367ea0"
        },
        {
          "bel": "p(INTERPRO:\"Heat shock protein 70 family\")",
          "concept": {
            "name": "Heat shock protein 70 family",
            "namespace": "INTERPRO"
          },
          "function": "Protein",
          "id": "43387e6260ac862bb69d16380eb79e5f"
        }
      ]
    },
    {
      "bel": "p(FPLX:HSP90)",
      "concept": {
        "name": "HSP90",
        "namespace": "FPLX"
      },
      "function": "Protein",
      "id": "1d25d355c41148f8c1322364b79179e4"
    },
    {
      "bel": "p(HGNC:AHSA1)",
      "concept": {
        "name": "AHSA1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "801b5a3d09f90703dda1464396c4924f"
    },
    {
      "bel": "p(HGNC:AKT1)",
      "concept": {
        "name": "AKT1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "2fe8184c6afa461574b1e1fba8b00dab"
    },
    {
      "bel": "p(HGNC:BAG1)",
      "concept": {
        "name": "BAG1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "e99a022dd6d96a105b9a599748e7cf66"
    },
    {
      "bel": "p(HGNC:BAG2)",
      "concept": {
        "name": "BAG2",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "1aa87e6eae4239d02cccdb3f23b02548"
    },
    {
      "bel": "p(HGNC:CDC37)",
      "concept": {
        "name": "CDC37",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "8ac61583b7b88b6635a828008797ef03"
    },
    {
      "bel": "p(HGNC:CDK5)",
      "concept": {
        "name": "CDK5",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "cb1e1b28f1d3fe30db837d601f26fe1b"
    },
    {
      "bel": "p(HGNC:FKBP5)",
      "concept": {
        "name": "FKBP5",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "6cdfe5e08dbab001c43d1af3146cfb92"
    },
    {
      "bel": "p(HGNC:GSK3B)",
      "concept": {
        "name": "GSK3B",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "8eaf29c9e491ff4e49619e77de92467c"
    },
    {
      "bel": "p(HGNC:HSF1)",
      "concept": {
        "name": "HSF1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "9f33a9782d13790c22a0e0748b7a2a35"
    },
    {
      "bel": "p(HGNC:HSPA8)",
      "concept": {
        "name": "HSPA8",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "1e0e1cda4e0ab830cc8bb12a7035a8b2"
    },
    {
      "bel": "p(HGNC:HSPB1)",
      "concept": {
        "name": "HSPB1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "d5b5de04c466b9b3d8edde293c1f2a4f"
    },
    {
      "bel": "p(HGNC:HSPH1)",
      "concept": {
        "name": "HSPH1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "946f5d979d6ba6c9a47e50bbd67ea9bc"
    },
    {
      "bel": "p(HGNC:MAPT)",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "7d1009217050e75d549c8c5aa83309a8"
    },
    {
      "bel": "p(HGNC:MAPT, pmod(CONSO:hyperphosphorylation))",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "0d2d8072f03dcdf148e658067d37b9cb",
      "variants": [
        {
          "concept": {
            "name": "hyperphosphorylation",
            "namespace": "CONSO"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT, pmod(Ph))",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "a8fb3a87d5a0672c07462bb17c8b0947",
      "variants": [
        {
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT, pmod(Ph, Ser, 202), pmod(Ph, Thr, 205))",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "3cbda9484b1c609131d91359822dc2c3",
      "variants": [
        {
          "code": "Ser",
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 202
        },
        {
          "code": "Thr",
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 205
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT, pmod(Ph, Ser, 396), pmod(Ph, Ser, 404))",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "4a1943ea35dd0f11cf4c30b8869a878e",
      "variants": [
        {
          "code": "Ser",
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 396
        },
        {
          "code": "Ser",
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 404
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT, var(\"?\"))",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "82ca363b9b9e9f7f2e880d0674096ecf",
      "variants": [
        {
          "hgvs": "?",
          "kind": "hgvs"
        }
      ]
    },
    {
      "bel": "p(HGNC:MARK2)",
      "concept": {
        "name": "MARK2",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "6e8b2d15698adf8fc72bb10d3a7e06b3"
    },
    {
      "bel": "p(HGNC:PPP2R5B)",
      "concept": {
        "name": "PPP2R5B",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "217d1abe4e816bb6aea7c116ae110853"
    },
    {
      "bel": "p(HGNC:PPP5C)",
      "concept": {
        "name": "PPP5C",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "35efd0a2d06ed8ef8a17c014d39f48da"
    },
    {
      "bel": "p(HGNC:PTGES3)",
      "concept": {
        "name": "PTGES3",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "f3cf891b5455730db56f755ea78283ad"
    },
    {
      "bel": "p(HGNC:STIP1)",
      "concept": {
        "name": "STIP1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "1afa5f431569f21a745c9ac99d1386a3"
    },
    {
      "bel": "p(HGNC:STUB1)",
      "concept": {
        "name": "STUB1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "d87d73cafef28fc2c05ea70f059c61a4"
    },
    {
      "bel": "p(HGNC:UBA2)",
      "concept": {
        "name": "UBA2",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "323fc386413cd10537097b7a2853e366"
    },
    {
      "bel": "p(HGNC:VHL)",
      "concept": {
        "name": "VHL",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "51ee7ec3981d10efa166f95b9b4fc8d0"
    },
    {
      "bel": "p(INTERPRO:\"Chaperone J-domain superfamily\")",
      "concept": {
        "name": "Chaperone J-domain superfamily",
        "namespace": "INTERPRO"
      },
      "function": "Protein",
      "id": "0b3db1de5a21d5d78cf0a952eb367ea0"
    },
    {
      "bel": "p(INTERPRO:\"HSP90, C-terminal domain\")",
      "concept": {
        "name": "HSP90, C-terminal domain",
        "namespace": "INTERPRO"
      },
      "function": "Protein",
      "id": "8a3e87a637932f989fd2e3abc8297716"
    },
    {
      "bel": "p(INTERPRO:\"Heat shock protein 70 family\")",
      "concept": {
        "name": "Heat shock protein 70 family",
        "namespace": "INTERPRO"
      },
      "function": "Protein",
      "id": "43387e6260ac862bb69d16380eb79e5f"
    },
    {
      "bel": "p(INTERPRO:\"Heat shock protein Hsp90, N-terminal\")",
      "concept": {
        "name": "Heat shock protein Hsp90, N-terminal",
        "namespace": "INTERPRO"
      },
      "function": "Protein",
      "id": "404ded91bc7dea3351f3a1d020bb4ad2"
    },
    {
      "bel": "p(INTERPRO:\"Tetratricopeptide repeat-containing domain\")",
      "concept": {
        "name": "Tetratricopeptide repeat-containing domain",
        "namespace": "INTERPRO"
      },
      "function": "Protein",
      "id": "16e58e08d1cf6be2ab6cf185802263ce"
    },
    {
      "bel": "path(CONSO:neurotoxicity)",
      "concept": {
        "name": "neurotoxicity",
        "namespace": "CONSO"
      },
      "function": "Pathology",
      "id": "f092504a78142cc0cb1a590cf3b073d3"
    },
    {
      "bel": "path(MESH:\"Alzheimer Disease\")",
      "concept": {
        "name": "Alzheimer Disease",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "2ae8307f5fd59056199369691367cc96"
    },
    {
      "bel": "path(MESH:Neoplasms)",
      "concept": {
        "name": "Neoplasms",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "721141fdf3882c4e50f26485962a29e4"
    },
    {
      "bel": "path(MESH:Tauopathies)",
      "concept": {
        "name": "Tauopathies",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "e7af59eca49dd3e30ab0fb75db41527a"
    },
    {
      "bel": "rxn(reactants(a(CHEBI:ATP)), products(a(CHEBI:\"phosphate(3-)\"), a(CHEBI:ADP)))",
      "function": "Reaction",
      "id": "a178fa592e459f0a70c24e6c5151b37c",
      "products": [
        {
          "bel": "a(CHEBI:\"phosphate(3-)\")",
          "concept": {
            "name": "phosphate(3-)",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "fb6fd08200f6469cca623b134c5ac56f"
        },
        {
          "bel": "a(CHEBI:ADP)",
          "concept": {
            "name": "ADP",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "1fd3a946ceefb4e6928ddd6a81a814b1"
        }
      ],
      "reactants": [
        {
          "bel": "a(CHEBI:ATP)",
          "concept": {
            "name": "ATP",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "08c2bd47cf55782389bbaba34887a39c"
        }
      ]
    }
  ]
}